Human capsaicin receptor and uses thereof

Abstract

This invention provides novel human capsaicin receptors and the nucleotide sequences encoding these receptors. Also provided are vectors encoding these receptors and mammalian and non-mammalian cells expressing these vectors. Further provided are assays for identifying compounds that modulate capsaicin receptors and diagnostic assays for capsaicin receptor polymorphisms and aberrant capsaicin receptor expression.

Description

BACKGROUND OF THE INVENTION

The sensation of pain can be triggered by any number of physical or chemical stimuli. In mammals, the peripheral terminals of a group of specialized small diameter sensory neurons, termed “nociceptors” mediate this response to a potentially harmful stimulus.

In efforts to discover better analgesics for the treatment of both acute and chronic pain, and to develop treatments for various neuropathic pain states, considerable research has been focused on the molecular mechanism of nociception. The response to heat, low extracellular pH, or capsaicin (the compound responsible for the hotness of hot peppers) is characterized by the persistent activation of nociceptors (Bevan and Gepetti, 1994, and Kress and Reeh, 1996). It has been shown that both heat and capsaicin are capable of activating dorsal root ganglion and trigeminal ganglion neurons via and influx of cations (Oh, et al. 1996, Kirshstein, et al. 1997). Additionally, moderately acidic conditions produce this response (Zeilhofer, et al., 1997) and also potentiate the response of nociceptors to heat and capsaicin (Kress, et al., 1996).

Capsaicin responses in isolated sensory neurons show dose-dependence and are also evoked by structural analogues of capsaicin (Szolcsanyi and Jancso-Gabor, 1975 and 1976). Resiniferatoxin (RTX), a natural product of Euphorbia plants is a particularly potent activator of the capsaicin response (Szallasi and Blumberg, 1989). Capsaicin and resiniferatoxin share a common vanilloid moiety, thus the capsaicin receptor is also termed the vanilloid receptor (VR). The capsaicin response is competitively inhibited by another structural analog, capsazepine (Bevan, et al., 1992) and by the non-selective cation channel blocker ruthenium red (Wood, 1988).

It was initially postulated that the VR is a non-selective cation channel with a preference for calcium. Consequently, a 45 Ca 2+ -uptake assay using intact rat dorsal root ganglion (DRG) neurons has been used extensively to characterize structure-activity relations for vanilloids. Specific binding of [ 3 H]RTX provided the first unequivocal proof for the existence of a VR and has furnished a new, biochemical tool to study VR pharmacology. Such studies, however, have been limited by the lack of availability of cloned VR species and sub-types, by the low levels of VR produced by the few cell types that naturally express such receptors in vivo, and by the limited expression levels heretofore obtained using transient recombinant expression technologies.

Interest in characterizing VRs led to the cloning of a functional rat capsaicin receptor (VR1), from a rat dorsal root ganglion cDNA library (Caterina, et al., 1997). The cDNA for the rat capsaicin receptor VR1 encodes an 838 amino acid protein (SEQ ID NO:9) with a predicted molecular mass of 95,000 Daltons. Sequence analysis suggests that the receptor is composed of a 432 amino acid hydrophilic amino terminus that contains a proline-rich region followed by three ankyrin repeat domains, a membrane bound region that includes 6 beta-sheet transmembrane domains as well as an additional membrane-associated region between transmembrane segments 5 and 6, and a 154 amino acid carboxy terminus.

VR1 is activated not only by vanilloids but also by noxious heat and low pH. As predicted, this VR1 is a relatively non-selective cation channel with a preference for calcium. In Xenopus oocytes expressing VR1, vanilloids evoke inward currents, with RTX being approximately 20-fold more potent (EC 50 =39 nM) than capsaicin (EC 50 =710 nM). In VR1-transfected mammalian (HEK293) cells, capsaicin induces whole-cell currents with a potency of 110 nM. Taken together, these results suggest that VR1 corresponds to the site in DRG neurons that mediates calcium uptake.

Homology searches comparing the cloned rat capsaicin receptor VR1 to other known ligand gated channels have revealed some related receptors. The most highly homologous protein identified to date is the recently identified rat vanilloid-receptor-like protein 1 (VRL-1) (Caterina, et al. 1999). This protein shares approximately 49% identical amino acid residues and overall is 66% similar in sequence to the rat capsaicin receptor, VR1, and is predicted to have a tertiary structure quite similar to that of the capsaicin receptor. While the VRL-1 protein has been reported to respond to high temperatures by allowing an influx of cations, it is not a capsaicin receptor, as it is insensitive to capsaicin and capsaicin analogues.

Another class of receptors that shows some homology to the capsaicin receptor is the TRP (transient release potential) family of putative store-operated calcium channels. (Caterina, et al., 1997) also known as “trp channels”. Members of this family of receptors mediate the entry of extracellular Ca 2+ in response to the depletion of intracellular Ca 2+ stores (Clapham, 1996). The capsaicin receptor, while mediating the entry of Ca 2+ and other cations in response to heat, low extracellular pH and capsaicin and related compounds, does not act as a store-operated calcium channel.

If vanilloid binding and calcium uptake are always mediated by the same receptor, a logical prediction would be that ligands mediating these two responses should display similar structure-activity relationships. With regard to DRG neurons expressing native VRs this is clearly not the case: structure-activity analysis of different vanilloid derivatives revealed that the various compounds have distinct potencies for receptor binding and for inducing 45 Ca 2+ -uptake in rat DRG neurons. Although some compounds, such as RTX-amide, bind to VRs and evoke calcium influx with similar potencies, other vanilloids show relative selectivity for one or the other response. RTX represents one extreme. It is approximately 25-fold more potent for binding (using intact rat DRG neurons the K d was reported to be 40 pM) than for inducing calcium uptake (EC 50 =1.0 nM). Capsaicin represents the opposite extreme. It evokes calcium influx with an EC 50 of 270 nM but inhibits [ 3 H]RTX binding with a 10-fold lower affinity of 3 uM. The most straightforward explanation appeared to be that RTX binding and calcium uptake detected two distinct classes of VRs. These putative receptors were referred to as R-type (preferentially labeled by RTX) and C-type (displaying a higher potency for capsaicin) VRs, respectively. This model was further supported by the identification of non-neuronal cell lines that exhibited calcium uptake in response to vanilloid stimulation (implying the presence of C-type VRs) but which lacked detectable RTX-specific binding sites.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 A. Specific binding of [ 3 H]resiniferatoxin to HEK 293 cells transfected stably with a cDNA encoding the rat VR1 (HEK293/VR1 cells). [ 3 H]Resiniferatoxin displays saturable specific binding to HEK293/VR1 cells. Binding data are from a single experiment; points are mean values of triplicate determinations; error bars indicate S.E.M. The binding curve was generated by a computer fit of the measured values to the Hill equation. Half-maximal binding occurred at a concentration of 56 pM [ 3 H]resiniferatoxin; the maximal receptor density was 222 fmol per one million cells. Note that the Hill coefficient (1.8) is indicative of positive binding cooperativity. Three additional experiments yielded similar results. Data are presented as the mean (+/−S.E.M), and binding parameters are set forth in Example 6, Results.

FIG. 1 B. Specific binding of [ 3 H]resiniferatoxin to HEK 293 cells transfected stably with a cDNA encoding the rat VR1 (HEK293/VR1 cells). Expanded view of the concentration range from 0-200 pM of the specific binding of [ 3 H]resiniferatoxin to HEK293/VR1 cells. As a result of the cooperativity index approaching 2, the specific binding curve is sigmoidal in this concentration range. Measured values are from FIG. 1 A. The binding curve is hypothetical and was computer-generated using the binding parameters from FIG. 1 A.

FIG. 1 C. Specific binding of [3H]resiniferatoxin to HEK 293 cells transfected stably with a cDNA encoding the rat VR1 (HEK293/VR1 cells). Scatchard plots of specific [3H] resiniferatoxin binding to HEX 293/VR1 cells and CHO/VR1 cells. Filled circles indicate data for HEK293/VR1 cells; data for CHO/VR1 cells are indicated by triangles. The Scatchard plots are convex due to the positive cooperativity of the binding. Also note that the B max value is approximately twice as high in CHO/VR1 as in HEK293/VR1 cells.

FIG. 2 . Scatchard plot of specific [ 3 H] resiniferatoxin binding to rat dorsal root ganglion membranes. Half-maximal binding occurred at a concentration of 60 pM [ 3 H]resiniferatoxin; the maximal receptor density was 302 fmol per one million cells. A Hill coefficient, or cooperativity index, of 1.5 was observed. Compare with FIG. 1 C and note that [ 3 H] resiniferatoxin binds to rat dorsal root ganglion membranes expressing native vanilloid receptors and to mammalian cells (HEK293 and CHO) transfected with the cloned rat vanilloid receptor VR1 with similar binding parameters. Results of a single experiment are shown; a second experiment yielded similar results.

FIG. 3 A. Inhibition of specific [ 3 H] resiniferatoxin binding as to HEK 293/VR1 cells by the typical vanilloid agonists olvanil and capsaicin, the novel vanilloids isovelleral and scutigeral, and the competitive vanilloid receptor antagonist capsazepine. Points represent values from 3 to 6 independent determinations; error bars indicate S.E.M. See Example 6, Results, for calculated K I values.

FIG. 3 B. Inhibition by olvanil, capsaicin, and capsazepine of specific [3H] resiniferatoxin binding to HEK293/VR1 cells and to CHO/VR1 cells. Open markers indicate data for HEK293/VR1 cells; closed markers indicate data for CHO/VR1 cells. HEK293/VR1 data are from FIG. 3 A. For CHO/VR1 cells, points represent mean values of 2 determinations; error bars indicate range.

FIG. 4 A. Time dependence of capsaicin and RTX-evoked calcium mobilization in CHO/VR1 cells. Time dependence of capsaicin-evoked calcium mobilization in CHO/VR1 cells in response to 3 nM, 30 nM and 3,000 nM capsaicin. In FIG. 4 A and FIG. 4 b , traces from a representative side-by-side comparison of capsaicin and resiniferatoxin effects are displayed. Note that these two typical vanilloid agonists display substantially different kinetics from the responses they evoke.

FIG. 4 B. Time dependence of resiniferatoxin-evoked calcium mobilization in CHO/VR1 cells in response to 0.01 nM, 1 M and 100 nM resiniferatoxin.

DESCRIPTION OF THE SEQUENCE LISTINGS

SEQ ID NO:1. Human capsaicin receptor cDNA.

SEQ ID NO:2. Human capsaicin receptor cDNA. Differs from SEQ ID NO:1 only in the 5′ and 3′ untranslated regions.

SEQ ID NO:3. DNA encoding Short form of Human capsaicin receptor.

SEQ ID NO:4. Protein encoded by both SEQ ID NO:1 and SEQ ID NO:2. Transmembrane domains span residues thusly: TM1=434-455, TM2=480-495, TM3=510-530, TM4=543-569, TM5=577-596, TM6=656-684.

SEQ ID NO:5. Protein encoded by SEQ ID NO:3. Transmembrane domains span residues thusly: TM1=434-455, TM2=480-495.

SEQ ID NO:6. Amino acid sequence of FLAG epitope.

SEQ ID NO:7. Amino acid sequence of His6x epitope.

SEQ ID NO:8. Rat capsaicin receptor VR1 cDNA sequence.

SEQ ID NO:9. Rat capsaicin receptor VR1 amino acid sequence.

SEQ ID NO:10. The DNA sequence of a 500 bp Bgl II fragment of the rat VR1 cDNA (used as a probe).

SEQ ID NO:11. The DNA sequence of an 830 bp BamHI/NcoI fragment of the rat VR1 cDNA (used as a probe).

SEQ ID NO:12. Forward primer used to clone rat VR1 cDNA.

SEQ ID NO:13. Reverse primer used to clone rat VR1 cDNA.

SUMMARY OF THE INVENTION

This invention relates to novel human capsaicin receptor polypeptides and the nucleotide sequences encoding them. Also included in this invention are nucleic acid vectors (e.g., plasmids) comprising the nucleotide sequence encoding these receptors, mammalian and non-mammalian cell lines comprising such vectors and thereby expressing at least one of the receptor polypeptides, and purified membranes obtained from such mammalian and non-mammalian cell lines. In certain preferred embodiments the polypeptides are full-length active human capsaicin receptor proteins that are capable of binding to capsaicin or capsaicin analogues. In other embodiments the receptors are naturally occurring truncated human capsaicin receptor proteins that are expressed at higher levels in bacterial cells than are full-length human capsaicin receptor proteins. Such truncated proteins are useful for bacterial expression e.g., for the production of immunogens for use in preparing anti-capsaicin receptor antibodies.

In another aspect, this invention relates to assays for identifying compounds that modulate capsaicin receptors, such assays requiring recombinantly expressed active human capsaicin receptor proteins that are capable of binding to capsaicin or capsaicin analogues. Cell lines that express the human capsaicin receptor are useful for screening compounds for either agonist, reverse agonist or antagonist activity at capsaicin receptors. Compounds that act as agonists at the human capsaicin receptor are useful as flavoring agents or animal repellents, while those that act as antagonists or reverse agonists may be useful as analgesics or anesthetics.

In a separate aspect this invention relates to diagnostic assays for capsaicin receptor polymorphisms and aberrant capsaicin receptor expression levels. Such assays are useful for identifying individuals that are either particularly susceptible or particularly insusceptible to the types of pain mediated by the capsaicin receptor and thereby for determining which individuals will benefit from and which will prove refractory to treatment with modulators of this receptor.

DETAILED DESCRIPTION OF THE INVENTION

Nucleic Acids

The present invention provides isolated nucleic acid molecules encoding human capsaicin receptors. Isolated nucleic acid molecules encoding human capsaicin receptors comprise DNA molecules, such as genomic DNA molecules, cDNA molecules, or RNA molecules. In one embodiment the isolated nucleic acid molecule is the cDNA sequence shown SEQ ID NO:1. In a separate embodiment the isolated nucleic acid molecule is the cDNA sequence shown is SEQ ID NO:2. In another embodiment the isolated nucleic acid molecule is the cDNA sequence shown in SEQ ID NO:3. SEQ ID NO:1 and SEQ ID NO:2 differ in their non-coding regions, while SEQ ID NO:3 encodes a shortened (truncated) form of the human capsaicin receptor, as well as containing a different 5′ non-coding region.

The invention also includes an isolated nucleic acid molecule encoding the amino acid sequence of SEQ ID NO:4 and an isolated nucleic acid molecule encoding the amino acid sequence of SEQ ID NO:5, in certain preferred embodiments the nucleic acid molecules encode polypeptides with amino acid sequences corresponding to the sequences starting with amino acid 2 (Lys) of SEQ ID NO:4 or SEQ ID NO:5. Also included is an isolated nucleic acid molecule encoding a human capsaicin receptor sequence comprising the amino acid sequence consisting essentially of SEQ ID NO:5.

It will be apparent to those skilled in the art that due to the degeneracy of the genetic code numerous variants of the described nucleic acid molecules can be created by substituting 1 or more codons without changing the encoded amino acid sequence of the protein product. Additionally, nucleic acid changes may be made in the non-coding region of the nucleic acid sequences without altering the amino acid sequence of the protein product.

The present invention also encompasses DNA and cDNA sequences that encode amino acid sequences which differ from those of the human capsaicin receptor but which do not produce phenotypic changes. Preferably such changes are conservative amino acid changes. By the term “conservative amino acid change” is meant any change from one amino acid to another amino acid considered to have similar characteristics (see, e.g., Schulz & Schirmer, 1990) as set forth in Table I hereto.

TABLE I
Amino Acids Grouped by Characteristics
		Large
Basic Side	Acidic Side	Aliphatic	Aromatic	Polar Side
Chains	Chains	Side Chains	Side Chains	Chains
Lysine,	Aspartate,	Leucine,	Phenylalanine,	Glycine,
Arginine,	Glutamate	Isoleucine,	Tyrosine,	Alanine,
Histidine		Valine	Tryptophan	Proline,
		Cysteine,		Serine,
		Methionine		Threonine,
				Asparagine,
				Glutamine

Also within the scope of the present invention are other changes to DNA and cDNA sequences encoding the amino acid sequences of SEQ ID NO:4 and SEQ ID NO:5 are in-frame additions of nucleic acid sequences encoding useful amino acid sequence tags. Such tags are useful as, e.g., antibody recognition sites and as sites contributing strong binding interaction characteristics (such as glutathione-S-transferase binding, biotin binding, or metal chelation binding) that are useful for facilitating protein purification via, e.g. affinity chromatography. Such amino acid sequences are well known in the art, and include, but are not limited to the His-6x epitope (SEQ ID NO:6), which chelates copper and other metal ions and is specifically bound by the Monoclonal Anti-polyhistidine Clone HIS-1 monoclonal antibody (Sigma, St. Louis No. H1029), and the FLAG epitope (SEQ ID NO:7), which is specifically bound by the FLAG-M2 monoclonal antibody (Sigma, St. Louis No. F3165). Techniques for making such modifications are also well known in the art, and may be readily carried out using routine methods or by using commercially available kits, for example, the Sigma Mammalian FLAG Expression Kits (Sigma, St. Louis, e.g., Nos. FL-MA and FL-MC).

Also included in the invention are DNA and cDNA sequences encoding human capsaicin receptors identical to those of SEQ ID NO:4 or SEQ ID NO:5, except in the regions encoding their transmembrane domains (as set forth below in the SEQUENCE LISTING). The transmembrane domains of the capsaicin receptor are believed to be β strands. Sequences consisting essentially of the amino acids Tyrosine, Tryptophan, Valine, Threonine, Glutamine, Methionine, Leucine, Isoleucine, Phenylalanine and Cysteine are known to have high propensities for forming β strands (Chou and Fasman, 1974). Substitution of nucleotides encoding any of these amino acids for nucleotides encoding other amino acids in the transmembrane regions of the capsaicin receptors of SEQ ID NO:4 and SEQ ID NO:5 will result in functional receptor translation products, and are within the scope of the present invention.

Polypeptides

This invention provides isolated human capsaicin receptor polypeptides having the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:5. In certain preferred embodiments the polypeptides have amino acid sequences corresponding to the sequences starting with amino acid 2 (Lys) of SEQ ID NO:4 or SEQ ID NO:5. The amino acid sequence given by SEQ ID NO:4 is the protein product encoded by both SEQ ID NO:1 and SEQ ID NO:2. The amino acid sequence given by SEQ ID NO:5 is the protein product encoded by SEQ ID NO:3.

This invention also encompasses human capsaicin receptors having amino acid sequences that further differ from those exemplified herein, but which do not exhibit phenotypic changes. Such amino acid sequences are described above in the discussion of nucleotide sequences, and further include human capsaicin receptors having amino acid sequences that differ from those of SEQ ID NO:4 and SEQ ID NO:5 in the transmembrane domains of the protein without eliminating capsaicin receptor binding or signaling functions. The regions of the amino acid sequences for the receptor considered to represent the transmembrane domains of the protein are annotated as TM1, TM2, TM3, TM4, TM5 and TM6 in the sequence listing for SEQ ID NO:4 and SEQ ID NO:5. It is predicted that the transmembrane domains of the capsaicin receptor are β strands. The amino acids Tyrosine, Tryptophan, Valine, Threonine, Glutamine, Methionine, Leucine, Isoleucine, Phenylalanine and Cysteine are known to have high propensities for being in β strands (Chou and Fasman, 1974). Amino acid sequences of the human capsaicin receptor having of any of these amino acids substituted for other amino acids in the transmembrane domains are encompassed by this invention.

Vectors Encoding the Human Capsaicin Receptor

The present invention additionally provides nucleic acid vectors comprising a nucleic acid sequence encoding a polypeptide with the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:5 or, in certain preferred embodiments, encoding amino acid sequences corresponding to the sequences starting with amino acid 2 (Lys) of SEQ ID NO:4 or SEQ ID NO:5. Such nucleic acid sequences include any of the above-described nucleic acid a sequences. Suitable vectors include, but are not limited to, a plasmid or a viral vectors. In order for the vector to be used for recombinant expression of a capsaicin receptor, the nucleic acid sequence encoding the receptor must be operatively linked to a nucleic acid sequence comprising at least one regulatory element in the appropriate orientation for expression. Such regulatory elements are well known to those of skill in the art. Preferred regulatory elements are heterologous regulatory elements, i.e., regulatory elements that are not naturally found operatively linked to nucleic acid sequences encoding human capsaicin receptor polypeptides. Such elements include those obtained from other mammalian species as well as those from non-mammalian vertebrates, invertebrates, microbes and viruses. Particualrly preferered regulatory elements are inducible elements, i.e., elements that do not always stimulate expression (or only stimulate relatively low levels of expression), but that respond to environmental stimuli by increasing expression levels of the operatively linked coding sequences. A preferred inducible element is the tetracycline repressible element found in the commercially available pTET OFF™ plasmid vector.

Propagation of the vectors of the invention in microbial hosts is facilitated by the presence in the vector of sequences that act as origins of replication for microbial DNA synthesis, but such microbial-specific sequences are considered to reduce the rate of success in generating certain recombinant cells (particularly in generating transgenic animals), and thus such microbial sequences may be beneficially excised (e.g., by restriction enzyme digestion) prior to the introduction of the vector into an animal cell (e.g., a vertebrate zygote).

The vectors of the invention may be transformed, transfected, microinjected, or otherwise introduced into suitable host cells to form host cell-vector systems for the expression of a polypeptide of the invention. In certain preferred embodiments, the polypeptide exhibits human capsaicin receptor binding and/or signaling activity.

This invention encompasses any of the above-described vectors adapted for infection or transformation of a bacterial cell. Bacterial expression systems for the expression of membrane receptor proteins are available (Muench, et al. 1995). Bacterial host vector systems are also useful in that (when the appropriate microbial origin of DNA replication is present in the vector) they allow the production of large quantities of DNA or (when an appropriate microbial RNA polymerase transcription initiation site is present in the appropriate orientation for RNA expression) of RNA encoding the polypeptides of the invention. A particularly preferred vector for the bacterial expression of the polypeptides of SEQ ID NO:5 is the be pRSET vector that is commercially available from Invitrogen (Carlsbad, Calif.). Protein expression using this vector can be conveniently induced by adding the lactose analog isopropylthiogalactoside (IPTG) to the bacterial culture medium.

This invention also encompasses the above-described vector adapted for expression in a eucaryotic cell (preferably an insect cell, an amphibian cell, or a mammalian cell) which vector further comprises heterologous regulatory elements allowing expression in the cell operatively linked to a nucleic acid molecule encoding at least one polypeptide of the invention, so as to permit expression thereof.

In one embodiment, the vector is adapted for expression in an insect cell. Plasmids commonly used to generate such vectors for this purpose include the BacPak8 and BacPak9 baculoviral vector plasmids (Clontech, Palo Alto, Calif.). These plasmid vectors typically include a multiple cloning site for the insertion in the appropriate orientation for expression of a DNA fragment comprising the sequence encoding the polypeptide to be expressed, such as any of the cDNA sequences of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3, a promoter sequence, a bacterial origin of DNA replication, and markers for antibiotic resistance.

This invention also encompasses the above-described vector adapted for expression in an amphibian cell, preferably a Xenopus laevis oocyte. Plasmids that may be used to generate such vectors for this purpose include the pcDNA3.1 vector (Invitrogen, Carlsbad, Calif.)

In a preferred embodiment, the vector is adapted for expression in a mammalian cell. An example of a plasmid commonly used to generate such vectors for expression of polypeptides (e.g., those of the present invention) in mammalian cells is pBK-CMV (Stratagene, La Jolla, Calif.) in which the regulatory elements include the cytomegalovirus promoter, which is activated by proteins that are ubiquitously expressed in vertebrate cells.

This invention provides plasmid vectors designated PT35, PT36, and PT44, which comprise the regulatory elements necessary for expression of DNA in a mammalian cell operatively linked to the DNA encoding human capsaicin receptor polypeptides of the invention in the appropriate orientation so as to permit expression.

These plasmids, PT35, PT36, and PT44 were deposited on Aug. 27, 1999 with the American Type Culture Collection (ATCC) 10801 University Blvd., Manassas, Va. 20110-2209, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and were accorded Patent Deposit Numbers PTA-576, PTA-577 and PTA-578, respectively. In accordance with 37 CFR 1.808 (a)(2), et seq., all restrictions imposed by the depositor on the availability to the public of the deposited materials will be irrevocably removed upon the granting of a U.S. patent from the present application.

Recombinant Cells Expressing the Human Capsaicin Receptor

In another aspect this invention provides a recombinant cell expressing the human capsaicin receptor polypeptides, said cell having been obtained by adding the above-described vectors to a host cell. Such host cells include cells from cell lines, cells from primary cultures, and ova and oocytes. A preferred cell of this type is a Xenopus laevis oocyte recombinantly expressing active human capsaicin receptor proteins of the invention. Other preferred recombinant cells of the invention include other amphibian cells, insect cells, or mammalian cells comprising at least one of the above-described vectors of the invention. The present invention thus includes such cells comprising such vectors comprising at least the coding regions of the nucleic acid sequences of at least one of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3, operatively linked to regulatory sequences in the appropriate orientation for the expression of the encoded polypeptides of the invention.

The vector may be added to the host cell by any of the means commonly practiced by those skilled in the art, including but not limited to infection, transformation, transfection or microinjection. Resulting recombinant cells (typically the progeny of the vector-containing host cell) will preferably express at least 2-fold greater capsaicin or capsaicin agonist binding activity (measured, e.g., as described for vanilloid binding in Example 6 hereto), or more preferably at least 10-fold greater binding activity, or most preferably at least 20-fold greater binding activity than a control host cell to which vector has not been added.

In one embodiment the recombinant cell is an insect cell comprising the above-described plasmid or vector. One commonly used insect cell protein expression system is that of Spodoptera frugiperda cells infected with a baculovirus vector.

The invention further provides a mammalian cell comprising the above-described vector. Both adherent and non-adherent mammalian cell are appropriate for expression of the human capsaicin receptor polypeptides of the invention. The mammalian cell may be a COS-7 cell, CHO cell, human embryonic kidney 293 cell (HEK 293), a U937 cell or any other suitable mammalian cell, including cells in primary cell cultures. The mammalian cell may also be prepared by generating a transgenic animal (preferably the animal is a rodent or a domestic livestock species such as a pig, cow, got, sheep, rabbit, or chicken). Methods for generating such transgenic animals are well known, and while often of low efficiency and technically demanding, are nonetheless routine in the art.

Artificially high expression levels of ion channels typically have toxic effects on cultured cells. Without wishing to be bound by any particular theory of operation, it is believed that when it occurs, such toxicity results from excess entry of ions (e.g., Ca 2+ ) into cells expressing artificially high levels of ion channels. The capsaicin receptors of the invention act as ion channels, and their expression at artificially high levels would thus be expected to be limited by such toxicity.

The present invention provides for recombinant mammalian cells (e.g., cells comprising an expression vector) expressing high levels of capsaicin receptors, or capable of expressing high levels of capsaicin receptors (e.g., upon derepression—for example removal of tetracycline from the growth medium of cells comprising expression vectors of the invention using the regulatory elements of the commercial pTET OFF™ inducible plasmid vector). Such cells express higher numbers of capsaicin binding sites than do naturally occurring cells, and are particularly useful for the preparation of membranes containing capsaicin receptors for use in binding assays for the identification of compounds that interact (preferably ones that specifically interact, e.g., by binding to the ligand-binding site of the receptor) with such receptors. Preferably, the recombinant cells of the invention are stably transfected cells.

Preferred cells express at least 5×10 4 capsaicin receptor ligand binding sites per cell. Preferably the cells express at least 1.5×10 5 such binding sites per cell. More preferably the cells express at least 3×10 5 , and even more preferably, 3×10 6 such binding sites per cell. Most preferably, the cells express at least 10 7 capsaicin receptor ligand binding sites per cell.

Preferred cells express at least 80 fmol of capsaicin receptor molecules per 10 6 cells. Preferably the cells express at least 250 fmol of capsaicin receptor molecules per 10 6 cells. More preferably the cells express at least 470 fmol of capsaicin receptor molecules per 10 6 cells and even more preferably at least 2 pmol of capsaicin receptor molecules per 10 6 cells. Most preferably, the cells express at least 16 pmol of capsaicin receptor molecules per 10 6 cells.

isolated Membranes of Recombinant Cells

In certain of its aspects the present invention provides preparations comprising isolated membranes of the recombinant cells of the invention. Preferably, the isolated membranes should exhibit capsaicin receptor ligand binding activity that is significantly greater, preferably at least 2-fold greater, more preferably at least 10-fold greater and most preferably at least 20-fold greater than that exhibited by control membranes isolated from a control host cell (e.g., a cell of the same cell line used to prepare the recombinant cell of the invention that does not contain any vector, or contains a control vector that does not encode a capsaicin receptor). Preferred membranes contain, per mg of total membrane protein, at least 415 fmol, preferably at least 1.25 pmol, even more preferably 2.35 pmol, particularly preferably 4.2 pmol, and most preferably at least 25 pmol of capsaicin receptor. Membranes can be isolated by any suitable method, such as any of the membrane preparation methods that are routinely used in the art.

Assays for Identifying Modulators of Capsaicin Receptors

In a final aspect, the invention provides methods for determining whether a compound can specifically bind to a capsaicin receptor and methods for determining whether a compound can modulate a capsaicin receptor as either an agonist or an antagonist. Agonist compounds are useful as analgesics. This counter-intuitive result is believed to follow from prolonged receptor desensitization that can occur following exposure to such compounds. Agonists, antagonists and reverse agonists are all useful as analgesics, as well as for the prevention and treatment of other conditions, such as treatment of urinary incontinence, prevention of urinary bladder hyper-reflexia and treatment of certain neuropathic pain states such as post herpetic neuralgia, diabetic neuropathy, carpal tunnel syndrome and phantom limb pain in amputees.

The invention thus provides assays for identifying compounds useful a) as analgesics, b) for the treatment of urinary incontinence, c) for the prevention of urinary bladder hyper-reflexia and d) for the treatment of neuropathic pain states (e.g., post herpetic neuralgia, diabetic neuropathy, carpal tunnel syndrome or phantom limb pain).

The invention in particular provides an assay for determining if a compound binds specifically to capsaicin receptors. This assay comprises contacting an experimental sample of either recombinant cells of the invention or isolated membrane preparation of such cells with a labeled capsaicin agonist and a test compound. A second control sample of either recombinant cells expressing the human capsaicin receptor or an isolated membrane preparation of such cells is contacted only with labeled capsaicin agonist. The unbound labeled agonist is removed from both samples and the amount of bound label in both the experimental sample and the control sample is determined. The amount of bound label in the experimental sample is compared to the amount bound label in the control sample. If the experimental sample exhibits a 2-fold decrease, or more preferably a 5-fold decrease or most preferably a 10-fold decrease in the amount of bound labeled capsaicin agonist the compound in the experimental sample is identified as binding specifically to capsaicin receptors.

In the above-described binding assay the labeled capsaicin agonist may be any agonist that is known to bind specifically to capsaicin receptors, such as capsaicin or resiniferatoxin and may be labeled by any detectable label. Detectable labels include, but are not limited to, radiolabels, fluorescent labels and colorometric labels. A particularly preferred labeled capsaicin agonist is [ 3 H] resiniferatoxin. Removal of unbound label may be accomplished by filtering or washing the samples but is not limited to these methods.

The invention also provides functional assays for identifying compounds that act as modulators of capsaicin receptors. Such assays can be used to classify compounds as agonists or antagonists of the capsaicin receptor.

This invention provides a method for determining whether a compound is a human capsaicin receptor agonist, which comprises contacting a recombinant cell of the invention with the compound under conditions that permit activation of a functional human capsaicin receptor response, detecting a functional increase in human capsaicin receptor activity, and there by determining whether the compound is a human capsaicin receptor agonist.

In one such embodiment the invention provides an assay for determining if a compound is an agonist of capsaicin receptors where the functional response is a change in the concentration of intracellular Ca 2+ . This assay comprises contacting a sample of recombinant cells expressing the human capsaicin receptor with an indicator of intracellular Ca 2+ concentration to yield indicator-loaded cells. After a sufficient incubation period excess indicator is removed from the cells to yield washed, indicator-loaded cells. A potential agonist compound is added to a sample of the washed, indicator-loaded cells. This sample is the experimental sample; the control sample is comprised of washed, indicator-loaded cells to which no potential agonist compound had been added. The concentrations of intracellular Ca 2+ experimental and control samples are measured by quantitating a change in the indicator of intracellular Ca 2+ . The concentration of intracellular Ca 2+ in the experimental cells that have been contacted with a potential agonist compound is compared to the concentration of intracellular Ca 2+ in the control cells. If the experimental sample exhibits a 1.5-fold increase, or more preferably a 5-fold increase or most preferably a 10-fold increase (or any significant increase) in the concentration of intracellular Ca 2+ the compound in the experimental sample is identified as a capsaicin receptor agonist. As used herein and in the Claims, a significant change (e.g., increse or decrese) is one that is significant to the p≦0.05 level in any standard parametric test of statistical significance, such as the F-test, or the Student's T-test.

Particularly preferred indicators of intracellular Ca 2+ concentration are membrane permeable calcium sensitive dyes, e.g., Fluo-3 and Fura-2. These dyes produce a fluorescent signal when bound to Ca 2+ . Removal of excess indicator from the indicator-loaded cells may be accomplished by washing or filtering cells, but is not limited to these methods.

This invention provides a method for determining whether a compound is a human capsaicin receptor antagonist, which comprises contacting a cell of the invention with the compound in the presence of a known capsaicin receptor agonist, such as capsaicin or resiniferatoxin, under conditions that permit the activation of a functional capsaicin receptor response, detecting a decrease in human capsaicin receptor activity, and thereby determining whether the compound is a human capsaicin receptor antagonist.

In one embodiment, the assay to identify compounds that act as antagonists of capsaicin receptors comprises contacting a test sample of recombinant cells expressing the human capsaicin receptor with an indicator of intracellular Ca 2+ concentration and a test compound (prefereably the cells are pre-loaded with the indicator). A second control sample of recombinant cells expressing the human capsaicin receptor is contacted only with the indicator of intracellular Ca 2+ concentration. After a sufficient incubation period excess indicator of intracellular Ca 2+ is removed from the test and control cells to yield washed, indicator-loaded test and control cells. An agonist of the capsaicin receptor is added to the washed, indicator-loaded cells to yield agonist-contacted test cells and agonist-contacted control cells. The concentration of intracellular Ca 2+ in the agonist-contacted test cells and the agonist-contacted control cells is measured by measuring changes in the properties of the indicator of intracellular Ca 2+ concentration. The concentration of intracellular Ca 2+ in the agonist-contacted test cells is compared to that in agonist-contacted control cells. A test compound for which this comparison indicates that the concentration of intracellular Ca 2+ in the agonist-contacted test cells is significantly less, to the p≦0.05 level, than the concentration of intracellular Ca 2+ in the agonist-contacted control cells is identified as an antagonist of capsaicin receptors.

As in the assay for agonists of the capsaicin receptor, particularly preferred indicators of intracellular Ca 2+ concentration are the membrane permeable calcium sensitive dyes, Fluo-3 and Fura-2. These dyes produce a fluorescent signal when bound to Ca 2+ . Removal of excess indicator from the indicator-loaded cells may be accomplished by any suitable method, such as washing or filtering cells.

The invention will now be further described with reference to the following examples.

EXAMPLES

Example 1

Isolation of Human Capsaicin Receptor DNA Clones

Poly A+ RNA was isolated from frozen human dorsal root ganglia. A complementary DNA (cDNA) library was constructed using the ZAP EXPRESS cDNA SYNTHESIS KIT and the ZAP EXPRESS cDNA GIGAPAK III GOLD CLONING KIT (Stratagene, La Jolla, Calif.) according to the manufacturer's instructions. This library contained approximately 1.1×10 6 independent clones. 1×10 6 plaque forming units (PFU) from this library were plated and transferred to nitrocellulose filters for hybridization screening. Two 32 P labeled probes were used for screening the filters. One probe, SEQ ID NO:10, corresponded to a 500 bp Bgl II fragment of the published rat Vanilloid Receptor 1 cDNA (VR1; Caterina, et al. 1997). The second probe, SEQ ID NO:11, corresponded to an 830 bp BamHI/Nco I fragment of VR1. Filters were hybridized with either probe overnight at 42° C. and subsequently washed at 55° C. in 0.2×SSC/0.1% SDS. Positive phage were isolated and re-screened to obtain a single (clonal) phage. The pBK-CMV phagemid was excised from the clonal lambda phage by using the EXASSIST Helper phage (Stratagene). The resulting plasmids were transformed into E. coli strain XLOLR (Stratagene). Plasmid DNA was isolated by maxi prep for sequencing. The nucleotide sequences of the EcoRI/XhoI inserts of the phagemid clones were determined with an ABI CYCLE SEQUENCING KIT (Perkin-Elmer Applied Biosystems, Foster City, Calif.).

Example 2

Recombinant Cells

A. Transiently Transfected Cells

Plasmids PT35, PT36 and PT44 were isolated from XLOLR E. coli and separately transfected into HEK 293T cells (Edge Biosystems, Gaithersville, Md.) by adding 2 μg plasmid DNA and 12 μl LIPOFECTAMINE Reagent (Life Technologies cat no. 10964-013, Life Technologies, Gaithersville, Md.) per 60 mm culture plate according to the manufacturer's instructions. Cells were grown for 24 hrs at 37° C. then reseeded onto 96-well plates suitable for use in the FLIPR™ Plate Reader (Molecular Devices, Sunnyvale Calif.). Cells were grown an additional 24-48 hours before assay.

Transfected cells were assayed for changes in detectible Ca 2+ levels using the Calcium mobilization assay described below in Example 5. The results of these experiments are set forth in Table II.

B. Stably Transfected Cells

Cells stably expressing the human capsaicin receptor are selected using the Neomycin resistance marker present in the PT35, PT36 and PT44 plasmids. HEK 293T cells transiently transfected with the PT35, PT36 or PT44 plasmids as described above are grown in media containing the antibiotic G418 for two weeks to isolate cell lines stably expressing the recombinantly expressed human capsaicin receptor.

C. Inducible Stably Transfected Cells

The cDNA encoding SEQ ID NO:4 is subcloned into the pTRE vector (Clontech, Palo Alto, Calif.) for recombinant expression in mammalian cells. Plasmids are transfected with LIPOFECTAMINE™ into Chinese Hamster Ovary (CHO) cells containing the pTET OFF™ Regulator plasmid (Clontech, Palo Alto, Calif.). In these cells, expression of the pTRE plasmid is repressed in the presence of tetracycline but is induced upon removal of the antibiotic. Stable clones are isolated in culture medium containing puromycin (10 μg/ml) and maintained in medium supplemented with tetracycline (1 μg/ml). Cells are grown without antibiotic for 48-72 hours prior to assay to facilitate maximal expression of the human capsaicin receptor.

Example 3

Purified Membranes of Cells Expressing the Human Capsaicin Receptor

The human capsaicin receptor-transfected HEK 293T cells of Example 2 were seeded into 96 well plates and grown to 70-90% confluency. Cells were harvested by centrifugation at 3500×g and washed once by resuspension in ice cold PBS containing protease inhibitors. Cells were lysed by POLYTRON (speed 5, 30 seconds) and centrifuged at 536×g for 10 minutes in order to remove DNA, cellular organelles, and unlysed cells. The supernatant, containing isolated membranes, was decanted to a clean centrifuge tube and centrifuged for 20 minutes at 40,000×g. The resulting pellet was washed twice in ice cold PBS and centrifuged again for 20 minutes at 40,000×g. The supernatant of this step was discarded. The protein concentration of the resulting membrane pellet was measured using the Bio-Rad (Bradford) protein assay. By this measure, a 1 liter culture of cells typically yielded 50-75 mg of total membrane protein.

Example 4

Radioligand Binding Assay for Modulators of Capsaicin Receptors

Binding studies with [ 3 H] resiniferatoxin (RTX) (NEN, Boston) were carried out according to the protocol of Szallasi, et. al (1992) in which non-specific RTX Binding is reduced by adding bovine α 1 -glycoprotein (100 μg per tube) after the binding reaction has been terminated. Binding assay mixtures were set up on ice and contained [ 3 H] RTX, non-radioactive ligands, 0.25 mg/ml bovine serum albumin (Cohn fraction V), and 5×10 4 -1×10 5 human capsaicin receptor-transfected HEK-293T cells. The final volume was adjusted to 500 μl (competition binding assays) or 1,000 μl (saturation binding assays) with the buffer described above. Non-specific binding was defined as that occurring in the if presence of 1 μM non-radioactive RTX. For saturation binding, [ 3 H] RTX was added in the concentration range of 7-1,000 pM, using 1 to 2 dilutions. Competition binding assays were performed in the presence of 60 pM [3H] RTX and various concentrations of competing ligands. The binding reaction was initiated by transferring the assay mixtures into a 37° C. water bath and was terminated following a 60 minute incubation period by cooling the tubes on ice. Membrane-bound RTX was separated from free RTX as well as the α 1 -glycoprotein-bound RTX by pelleting the membranes in a Beckman 12 benchtop centrifuge for 15 minutes at 14,000×g. The radioactivity of membrane-bound RTX was determined by scintillation counting. Equilibrium binding parameters were determined by fitting the Hill equation to the measured values (Szallasi, et al., 1993) with the aid of the computer program Fit™ (Biosoft, Ferguson, Mo.).

Example 5

Calcium Mobilization Assays

A. Response to Capsaicin or Resiniferatoxin

Human capsaicin receptor transfected HEK 293T cells were seeded into 96 well plates and grown to 70-90% confluency. The cells were then washed once with Krebs Ringer solution. Fluo-3 (Molecular Probes, Eugene, Oreg.) calcium sensitive dye (10 ug/mL) was added and incubated with the cells at room temperature for 1 to 2 hours. The 96 well plates were then washed to remove excess dye. Fluorescence response was monitored upon the addition of either 300 nM capsaicin or 30 nM resiniferatoxin by a FLIPR™ plate reader (Molecular Devices, Sunnyvale Calif.) by excitation an 480 nM and emission at 530 nM. Cells transfected with plasmids PT35 and PT44, encoding the full length human capsaicin receptor (SEQ ID NO:1 and SEQ ID NO:2), typically exhibited signals of 5,000-8,000 Arbitrary Fluorescent Light Units in response to agonist.

TABLE II
Cell Type Ave Max Response (RFU)
Wild-Type 843
PT35      7257
PT36      805
PT44      5529
Measurement of intracellular calcium levels in the presence of capsaicin. HEK 293T cells transiently transfected with the indicated plasmids were exposed to 300 nM capsaicin. Intracellular calcium levels were quantitated on the FLIPR plate reader. Data are shown in Relative Fluorescent Units (RFU).

B. Assays for the Identification of Receptor Agonists and Antagonists

The calcium mobilization assay described above may be adapted for identifying test compounds as having agonist or antagonist activity at the human capsaicin receptor.

In order to identify agonist compounds, recombinant cells of the invention are washed and incubated with Fluo-3 dye as described above. A subset of the incubated cells are then exposed to a 1 μM concentration of at least one candidate agonist compound and the fluorescence response is monitored using a FLIPR™ plate reader (Molecular Devices, Sunnyvale, Calif.). Agonist compounds elicit a fluorescence response at least 2-fold that of recombinant cells exposed only to Fluo-3 dye. Preferred agonists elicit a fluorescence response at least 10 fold, and more preferred agonists elicit a fluorescence response at least 20-fold that of recombinant cells exposed only to Fluo-3 dye.

In order to identify antagonist compounds, recombinant cells of the invention are washed an incubated with Fluo-3 dye as described above. One hour prior to measuring the fluorescence signal, a subset of the cells is incubated with a 1 μM concentration of at least one candidate antagonist compound. The fluorescence response upon the subsequent addition of either 300 nM capsaicin or 10 nM resiniferatoxin is monitored using a FLIPR™ plate reader (Molecular Devices). Agonist compounds elicit at least a 2-fold decrease in the fluorescence response relative to that measured in the presence of capsaicin or RTX alone. Preferred antagonist compounds elicit at least a 10 fold, and more preferred antagonists at least a 20-fold decrease in the fluorescence response relative to that measured in the presence of capsaicin or RTX alone.

Example 6

Characterization of Capsaicin Receptors Expressed at High Levels in Cultured Cells

[ 3 H]Resiniferatoxin (RTX) binding and calcium uptake by rat dorsal root ganglion (DRG) neurons show distinct structure-activity relations, suggestive of independent vanilloid receptor (VR) subtypes. To evaluate the hypothesis that binding and calcium uptake detect two distinct classes of VRs in DRG neurons, characterization of RTX binding to the rat capsaicin receptor, VR1, expressed in HEK293 and CHO cells and comparison of the structure-activity relations with those for calcium mobilization was tested. In these binding experiments both typical (capsaicin and olvanil) and novel (isovelleral and scutigeral) vanilloids were included, as well as the competitive VR antagonist capsazepine. Vanilloid binding to HEK293/VR1 cells was compared to that measured in rat DRG neurons expressing native VRs. Calcium mobilization in HEK293/VR1 or CHO/VR1 cells was determined in response to RTX, olvanil, and capsaicin, using a fluorescent method. In addition, capsaicin-induced calcium mobilization in the VR1-transfected cells was measured in the presence of capsazepine or the so-called functional VR antagonist, ruthenium red. Agonist and antagonist potencies determined in the calcium mobilization assays using HEK293/VR1 or CHO/VR1 cells were compared to values measured previously in this laboratory for vanilloid-induced 45 Ca 2+ -uptake by intact rat DRG neurons.

HEK293/VR1 cells and CHO/VR1 cells bound [ 3 H]RTX with affinities of 84 pM and 103 pM, respectively, with a positive cooperativity (Hill numbers were 2.1 and 1.8). These binding parameters are similar to those determined using rat DRG membranes expressing native rat VRs (a K d of 70 pM and a Hill number of 1.7). The typical vanilloid agonists olvanil and capsaicin inhibited [ 3 H]RTX binding to HEK293/VR1 cells with K i values of 0.4 μM and 4.0 μM, respectively. The corresponding values in DRG membranes were 0.3 μM and 2.5 μM. HEK293/VR1 cells and DRG membranes also recognized the novel vanilloids isovelleral and scutigeral with similar affinities (18 and 20 μM in HEK293/VR1 cells; 24 and 21 μM in DRGs). The competitive vanilloid receptor antagonist capsazepine inhibited [ 3 H]RTX binding to HEK293/VR1 cells with a K i value of 6.2 μM, and to DRG membranes with an affinity of 8.6 μM. RTX and capsaicin induced calcium mobilization in HEK293/VR1 cells with EC 50 values of 4.1 nm and 82 nM, respectively. Thus, the relative potencies of RTX (more potent for binding) and capsaicin (more potent for calcium mobilization) are similar in DRG neurons and cells transfected with VR1. We conclude that VR1 may account for both the ligand binding and calcium uptake observed in rat DRG neurons.

Experimental Procedures

Materials. [ 3 H]Resiniferatoxin (RTX; 37 Ci/mmol) was synthesized by the Chemical Synthesis and Analysis Laboratory, NCI-FCRDC, Frederick, Md. Nonradioactive RTX was purchased from Alexis Corp. (San Diego, Calif.) and capsazepine was from RBI (Natick, Mass.). Olvanil was a generous gift from Procter and Gamble Corp. (Cincinnati, Ohio). Isovelleral and scutigeral were donated by Olov Sterner (Lund Univ., Sweden). All the other chemicals used were purchased from Sigma (St. Louis, Mo.) unless indicated otherwise.

Molecular Biology. A cDNA encoding the rat vanilloid receptor VR1 was cloned from rat dorsal root ganglion (DRG) total RNA by reverse transcription-polymerase chain reaction using primers based on the published nucleotide sequence (Caterina et al., 1997). The forward primer is set forth below as SEQ ID NO:12 and the reverse primer is set forth below as SEQ ID NO:13. A 2.7 kb cDNA was isolated and the nucleotide sequence was verified to be identical to the published sequence, SEQ ID NO:8. This cDNA was subcloned into pcDNA3.1 (Invitrogen, Carlsbad, Calif.) and pTRE (Clontech, Palo Alto, Calif.) for recombinant expression in mammalian cells of the encoded VR1 polypeptide, SEQ ID NO:9.

Cell Culture. The pcDNA3.1 VR1 plasmid was transfected into human embryonic kidney (HEK293) cells using standard methods. These transfected cells were selected for two weeks in media containing G418 (400 μg/ml) and then maintained as a pool of stably transfected cells. The pTRE VR1 plasmid was transfected into Chinese Hamster Ovary (CHO) cells containing the pTet Off Regulator plasmid (Clontech). In these cells, expression of the pTRE plasmid is repressed in the presence of tetracycline but is induced upon removal of the antibiotic. Stable clones were isolated in culture medium containing puromycin 10 (μg/ml) and maintained in medium supplemented with tetracycline (1 μg/ml) Cells utilized for assays were grown in culture medium without antibiotic for 48-72 hours prior to use. For radioligand binding experiments, cells were seeded in T175 cell culture flasks in media without antibiotics and grown to approximately 90% confluency. The flasks were then washed with PBS and harvested in PBS containing 5 mM EDTA. The cells were pelleted by gentle centrifugation and stored at −80° C. until assayed. For calcium mobilization assays, cells were seeded into 96-well plates and grown to 70-90% confluency.

Membrane Preparations. Female Sprague-Dawley rats weighing 200-250 g were euthanized under CO 2 anesthesia. The spinal columns were opened and DRGs were collected from all levels into ice-cold physiological saline. DRGs were disrupted with the aid of a tissue homogenizer in an ice-cold buffer (pH 7.4) containing (in mM) KCl 5, NaCl 5.8, CaCl 2 0.75, MgCl 2 2, sucrose 320, and HEPES 10. Tissue homogenates were first centrifuged for 10 min at 1000×g (4° C.) to remove the nuclear fraction and debris and then the supernatant from the first centrifugation was further centrifuged for 30 min at 35,000×g (4° C.) to obtain a partially purified membrane fraction. Membranes resuspended in the homogenization buffer were stored at −80° C. until assayed.

Radioligand Binding. Binding studies with [3H]RTX were carried out according to a published protocol (Szallasi et al., 1992) in which non-specific RTX binding is reduced by adding bovine alpha, acid glycoprotein (100 μg per tube) after the binding reaction has been terminated. Binding assay mixtures were set up on ice and contained [ 3 H]RTX, non-radioactive ligands, 0.25 mg/ml bovine serum albumin (Cohn fraction V), and either 5×10 4 -×10 5 VR1-transfected cells or isolated DRG membranes corresponding to 40 μg of DRG membrane protein. The final volume was adjusted to 500 μl (competition binding assays) or 1,000 μl (saturation binding assays) with the ice-cold HEPES (pH 7.4) buffer solution described above. Non-specific binding was defined as that occurring in the presence of 1 μM non-radioactive RTX. For saturation binding, [ 3 H]RTX was added in the concentration range of 7-1,000 pM, using 1 to 2 dilutions. Competition binding assays were performed in the presence of 30 pM (for DRG membranes) or 60 pM (for VR1-transfected cells) [ 3 H]RTX and various concentrations of competing ligands. The binding reactions were initiated by transferring the assay mixtures into a 37° C. water bath and were terminated following a 60 min incubation period by cooling the tubes on ice. Membrane-bound RTX was separated from free, as well as any alpha 1 -acid glycoprotein-bound RTX, by pelleting the membranes in a Beckman 12 benchtop centrifuge (15 min, maximal velocity) and the radioactivity determined by scintillation counting. Equilibrium binding parameters were determined by fitting the allosteric Hill equation to the measured values with the aid of the computer program Fit™ (Biosoft, Ferguson, Mo.) as described previously (Szallasi et al., 1993).

Calcium Mobilization Assays. VR1-transfected cells were seeded into 96-well plates and grown to 70-90% confluency. The cells were then washed once with Krebs-Ringer HEPES buffer (25 mM HEPES, 5 nM KCl, 0.96 mM NaH 2 PO 4 , 1 mM MgSO 4 , 2 mM CaCl 2 , 5 mM glucose, 1 mM probenecid, pH 7.4) and resuspended and incubated for 1-2 hours in the above buffer supplemented with FLUO3-AM (2.5-10 μg/ml; Teflabs, Austin, Tex. or Molecular Probes, Eugene, Oreg.) at 37° C. in an environment containing 5% CO 2 . In some experiments (as indicated below in the RESULTS), the Krebs-Ringer HEPES buffer was also supplemented with 1 mg/ml bovine serum albumin (Cohn fraction V). The wells were then washed twice with Krebs Ringer HEPES buffer. Agonist (olvanil, capsaicin, or RTX)-induced calcium mobilization was monitored using either FLUOROSKAN ASCENT (Labsystems, Franklin, Mass.) or FLIPR (Molecular Devices, Sunnyvale, Calif.) instruments. Similarly, varying concentrations of the antagonists ruthenium red or capsazepine were added to cells concurrently with agonist (25-50 nM capsaicin). Fluorescence data were collected to 60-180 seconds and the maximum fluorescence signal was determined. For the capsaicin- and olvanil-induced calcium responses, data obtained between 30 and 60 seconds after agonist application were used to generate the EC 50 values. Kaleidagraph software (Synergy Software, Reading, Pa.) was utilized to fit the data to the equation:

y=a *(1/(1+( b/x ) c ))

to determine the EC 50 for the response. In this equation, y is the maximum fluorescence signal, x is the concentration of the agonist or antagonist, a is the E max , b corresponds to the EC 50 or IC 50 value, and finaly, c is the Hill coefficient.

Results

Rat Capsaicin Receptor VR1-transfected Mammalian Cells (HEK293 and CHO) and Rat DRG Membranes Expressing Native Rat Vanilloid Receptors Bind [ 3 H]RTX with Similar Parameters.

The association of [ 3 H]RTX (60 pM) to VR1 expressed on HEK293 cells was rapid: within 10 min the specific binding attained approximately 90% of its peak value and it then remained on a plateau between 20 min and 60 min of incubation (a single experiment; data not shown). If dissociation was initiated following a 60 min association, it could be fitted to a 1st order decay curve, yielding a dissociation constant of 0.12+/−0.02 min−1 (two determinations; data not shown). Based on these preliminary experiments, an incubation period of 60 min was selected for the equilibrium binding studies.

[ 3 H]RTX (7-1,000 pM) displayed saturable binding to HEK293/VR1 cells (FIG. 1 A). The half-maximal binding occurred at 84+/−11 pM (mean+/−S.E.M.; 4 determinations); at the K d , non-specific binding represented approximately 20% of the total binding (not shown). The saturation binding curve was sigmoidal, indicating positive cooperativity (FIG. 1 B). A fit to the allosteric Hill equation yielded a cooperativity index of 2.1+/−0.2 (mean+/−S.E.M.; 4 determinations). This binding behavior results in a convex Scatchard plot (FIG. 1 C). The B max value was 250+/−24 fmol/10 6 cells (mean+/−S.E.M.; 4 determinations), corresponding to a receptor density of 1.5×10 5 binding sites per cell. CHO/VR1 cells bound RTX with similar affinity (a K d of 103+/−13 pM; mean+/−range; 2 determinations) and cooperativity values (a Hill number of 1.9+/−0.1; mean +/−range; 2 experiments). The maximal receptor density was, however, approximately two-fold higher than in the HEK293/VR1 cells (470+/−30 fmol/10 6 cells; mean+/−range; 2 determinations) (FIG. 1 C). The VR1-transfected cells lines bound RTX with parameters similar not only to each other but also to rat DRG membranes expressing native vanilloid receptors (FIG. 2 ). DRG membranes bound [ 3 H]RTX with a K d of 70+/−10 pM and a B max of 290+/−10 fmol/mg protein (mean+/−range; 2 determinations); the cooperativity index was 1.9+/−2 (mean+/−range; 2 determinations).

Although the CHO/VR1 cells provided a higher level of specific binding, HEK293/VR1 cells were chosen for detailed further analysis for a better comparison with the literature (Caterina et al., 1997; Tominaga et al., 1998).

Vanilloid Agonists and the Antagonist Capsazepine Inhibit [ 3 H]RTX Binding by VR1-transfected Mammalian Cells and DRG Membranes, Respectively, with Similar Affinities.

For the pharmacological characterization of the RTX-recognition site on rat VR1 expressed in HEK293 cells, four agonists (olvanil, capsaicin, isovelleral, and scutigeral) and an antagonist (capsazepine) were selected (FIG. 3 ). K i values of the agonists were the following: olvanil, 0.4+/−0.1 μM (n=4); capsaicin, 4.0+/−0.8 μM (n=6); isovelleral, 20+/−4 μM (n=3); and scutigeral, 18+/−3 μM (n=3); all values are mean+/−S.E.M. The competitive antagonist capsazepine inhibited [ 3 H]RTX binding with a K i of 6.2+/−0.7 μM (mean+/−S.E.M.; 5 experiments). These K i values are similar to those determined using rat DRG membranes: olvanil, 0.3+/−0.1 μM; capsaicin, 2.5+/−1.1 μM; isovelleral, 24+/−4 μM; scutigeral, 21+/−3 μM; and capsazepine, 8.6+/−3.5 μM (mean+/−S.E.M.; 3 experiments; Table III). The binding affinities of olvanil, capsaicin and capsazepine were also determined using CHO/VR1 cells: K i values were 0.26+/−0.5 μM, 1.3+/−0.4 μM, and 6.6+/−1.4 μM, respectively (mean+/−range; 2 determinations; TABLE III).

	TABLE III
	Rat dorsal root ganglion
	neurons	CHO/VR1 cells
	Binding	45 Ca 2+−	Binding	Ca 2+−
	affinity	uptake	affinity	mobilization
Ligand	(nM)	(EC 50 , nM)*	(nM)	(EC 50 , nM)
Resinifera-	0.07	1	0.13	1.4
toxin
capsaicin	2,500	340	1,700	38
olvanil	300	170**	260	216
capsazepine***	8,600	271	5,100	140 (1,100)
Ruthenium	no effect	790	no effect	210
red
Values are means of at least 4 independent determinations.
*From Ács, G. et al. (1996) Mol. Brain Res. 35: 173-182.
**From Walpole, C. S. J. and Wrigglesworth, R. (1993) in Capsaicin in the Study of Pain
***For capsazepine, K i values are given; the values in parenthesis (1,100 nM) were obtained in the absence of bovine serum albumin, 1 mg/ml.

Characterization of Rat Capsaicin Receptor VR1-transfected Mammalian Cells in the Calcium Mobilization Assay Using Various Vanilloid Compounds.

Capsaicin induced calcium mobilization in HEK293/VR1 cells and CHO/VR1 cells with EC 50 values of 82+/−17 nM (mean+/−S.E.M.; n=4) and 38+/−16 nM (mean+/−S.E.M.; n=5), respectively. RTX was more than an order of a magnitude more potent in both cell lines; EC 50 values were 4.1+/−1.3 nM in HEK293/VR1 cells (mean+/−S.E.M.; n=5), and 1.4+/−0.8 nM in CHO/VR1 cells (mean+/−S.E.M.; n=4). Capsaicin and RTX differed not only in potency in the calcium mobilization assay, but also in the kinetics of the response as shown by FIG. 4 . Using 30 nM capsaicin, a concentration close to the EC 50 in CHO/VR1 cells, led to rapid calcium mobilization responses: the maximal fluorescence change occurred within 30 sec. (30 μM capsaicin) to 50 sec. (3 nM capsaicin) By contrast, RTX-evoked calcium mobilization became detectable only after an initial delay (compare FIG. 4 A and FIG. 4 B). The calcium mobilization response to capsaicin achieved its peak value within 1 min. and then started to decline, suggestive of the development of tachyphylaxis or due to some other aspect of channel gating (FIG. 4 A). By contrast, unless high RTX concentrations were used (such as 100 nM, a value almost 100-fold higher than the EC 50 ), resiniferatoxin application resulted in slowly developing but persistent calcium currents. Calcium mobilization in response to 1 nM RTX increased steadily over a 3 min. period after challenge, approaching the maximal response evoked by 100 nM RX ( FIG. 4B ) This difference between the kinetics of capsaicin-induced and RTX-induced responses, however, disappeared when high, supramaximal doses were used (30 uM capsaicin or 100 nM RTX; compare FIG. 4 A and FIG. 4 B). Olvanil evoked the calcium response in CHO/VR1 cell with a potency of 22+/−6 nM (mean+/−S.E.M.; n=7). The time-course of the olvanil-induced calcium mobilization response was similar to that triggered by capsaicin (not shown). When 25 nM capsaicin was administered to evoke calcium mobilization, capsazepine inhibited this response with an IC 50 value of 2.4+/−0.5 uM (mean+/−S.E.M.; n=6). This value was, however, shifted by almost an order of magnitude in the presence of 1 mg/ml bovine serum albumin to yield an IC 50 value of 0.33+/−0.03 uM (mean+/−S.E.M.; n=5). For the other vanilloids tested in this study, the presence or absence of bovine serum albumin had no detectable influence on the calcium mobilization potency. With an IC 50 of 210+/−30 NM (mean+/−S.E.M.; n=7), the functional antagonist ruthenium red was similar in potency to capsazepine in ability to prevent calcium mobilization by capsaicin.

A further discussion of these results can be found in Szallasi et al., 1999.

Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Various modifications of the described modes for carrying out the invention that are obvious to those skilled in the relevant arts are within the scope of the invention. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention, which will be limited only by the appended claims.

REFERENCES CITED

Ács, G.,Lee, J., Marquez, V. E., and Blumberg, P. M. (1996) Mol. Brain Res . 35: 173-182.

Bevan, S. and Geppetti, P. (1994) Trends Neurosci . 17: 509-512.

Caterina, M. J., Schumacher, M. A., Tominaga, M., Rosen, T. A., Levine, J. D. and Julius, D., (1997) Nature 389: 816-824.

Caterina, M. J., Rosen, T. A., Tominaga, M., Brake, A. J., and Julius, D. (1999) Nature 398: 436-441.

Chou, P. Y. and Fasman G. D. (1974) Biochemistry 13: 222-244.

Clapham, D. E. (1996) Neuron 16: 1069-1072.

Julius, D., Caterina, M., and Brake, A. WIPO-PCT publication No. WO 99/09140.

Kirshstein, T., Busselberg, D., Treede, R. D. (1997) Neurosci. Lett . 231(1): 33-36.

Kress, M., Fetzer, S., Reeh, P. W. and Vyklicky (1996) Neurosci. Lets . 211: 5-8.

Kress, M. and Reeh, P. W. (1996) in Neurobiology of Nociceptors (Cervero, F. and Belmonte, C., eds.), 258-297, Oxford University Press.

Muench, G., Walker, P., Shine, J. and Herzog, H. (1995) Recept. Channels 3(4): 291-297.

Schulz, G. E. and Schirmer, R. H. (1990) in Principles of Protein Structure , Charles Cantor, editor, p. 14-16, Springer-Verlag, NY

Oh, U., Hwang, S. W. and Kim, D. (1996) J. Neurosci. 16: 1659-1667.

Szallasi, A. and Blumberg, P. M. (1989) Neuroscience 30: 515-520.

Szallasi, A., Lewin, N. E. and Blumberg, P. M. (1992) J. Pharmacol. Exp. Ter . 262: 883-888.

Szallasi, Lewin, N. E. and Blumberg, P. M. (1993) J. Pharmacol. Exp. Ther . 266: 678-683.

Szallasi, A., Blumberg, P. M., Annicelli, L. L., Krause, J., and Cortright, D. N. (1999) Mol. Pharmacol . 56(3): 581-7.

Szolcsanyi, J and Jancso-Gabor, A. (1975) Drug Res . 25: 1877-1881.

Szolcsanyi, J and Jancso-Gabor, A. (1976) Drug Res . 26: 33-37.

Tominaga, M., Caterain, M. J., Malmber, A. B., Rosen, T. A., Gilbert, H., Skinner, K., Raumann, B. E., Basbaum, A. I. and Julius, D. (1998) Neuron 21: 531-543.

Walpole, C. S. J. and Wrigglesworth, R. (1993) in Capsaicin in the Study of Pain (Wood, J. N., ed.) pp. 63-82, Academic Press, San Diego.

Zeilhofer, H. U., Kress, M. and Swandulla, D. (1997) J. Physiol . 503: 67-78.

SEQUENCE LISTING
<160> NUMBER OF SEQ ID NOS: 13
<210> SEQ ID NO 1
<211> LENGTH: 4203
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 1
ccgaagggcg tccacagcga ctcctgctat gcagggcagc tgctgccagg gccgggcccg     60
ggaccccacg gaggcgggga gaccactctt ctcccacacg agcccagctc tcccttcgag    120
tagcaaccgc cttcaagctc acaagcaccc gtgggcctgg ggtgtgcctg cgtctagctg    180
gttgcacact gggccacaga ggatccagca aggatgaaga aatggagcag cacagacttg    240
ggggcagctg cggacccact ccaaaaggac acctgcccag accccctgga tggagaccct    300
aactccaggc cacctccagc caagccccag ctctccacgg ccaagagccg cacccggctc    360
tttgggaagg gtgactcgga ggaggctttc ccggtggatt gccctcacga ggaaggtgag    420
ctggactcct gcccgaccat cacagtcagc cctgttatca ccatccagag gccaggagac    480
ggccccaccg gtgccaggct gctgtcccag gactctgtcg ccgccagcac cgagaagacc    540
ctcaggctct atgatcgcag gagtatcttt gaagccgttg ctcagaataa ctgccaggat    600
ctggagagcc tgctgctctt cctgcagaag agcaagaagc acctcacaga caacgagttc    660
aaagaccctg agacagggaa gacctgtctg ctgaaagcca tgctcaacct gcacgacgga    720
cagaacacca ccatccccct gctcctggag atcgcgcggc aaacggacag cctgaaggag    780
cttgtcaacg ccagctacac ggacagctac tacaagggcc agacagcact gcacatcgcc    840
atcgagagac gcaacatggc cctggtgacc ctcctggtgg agaacggagc agacgtccag    900
gctgcggccc atggggactt ctttaagaaa accaaagggc ggcctggatt ctacttcggt    960
gaactgcccc tgtccctggc cgcgtgcacc aaccagctgg gcatcgtgaa gttcctgctg   1020
cagaactcct ggcagacggc cgacatcagc gccagggact cggtgggcaa cacggtgctg   1080
cacgccctgg tggaggtggc cgacaacacg gccgacaaca cgaagtttgt gacgagcatg   1140
tacaatgaga ttctgatgct gggggccaaa ctgcacccga cgctgaagct ggaggagctc   1200
accaacaaga agggaatgac gccgctggct ctggcagctg ggaccgggaa gatcggggtc   1260
ttggcctata ttctccagcg ggagatccag gagcccgagt gcaggcacct gtccaggaag   1320
ttcaccgagt gggcctacgg gcccgtgcac tcctcgctgt acgacctgtc ctgcatcgac   1380
acctgcgaga agaactcggt gctggaggtg atcgcctaca gcagcagcga gacccctaat   1440
cgccacgaca tgctcttggt ggagccgctg aaccgactcc tgcaggacaa gtgggacaga   1500
ttcgtcaagc gcatcttcta cttcaacttc ctggtctact gcctgtacat gatcatcttc   1560
accatggctg cctactacag gcccgtggat ggcttgcctc cctttaagat ggaaaaaatt   1620
ggagactatt tccgagttac tggagagatc ctgtctgtgt taggaggagt ctacttcttt   1680
ttccgaggga ttcagtattt cctgcagagg cggccgtcga tgaagaccct gtttgtggac   1740
agctacagtg agatgctttt ctttctgcag tcactgttca tgctggccac cgtggtgctg   1800
tacttcagcc acctcaagga gtatgtggct tccatggtat tctccctggc cttgggctgg   1860
accaacatgc tctactacac ccgcggtttc cagcagatgg gcatctatgc cgtcatgata   1920
gagaagatga tcctgagaga cctgtgccgt ttcatgtttg tctacatcgt cttcttgttc   1980
gggttttcca cagcggtggt gacgctgatt gaagacggga agaatgactc cctgccgtct   2040
gagtccacgt cgcacaggtg gcgggggcct gcctgcaggc cccccgatag ctcctacaac   2100
agcctgtact ccacctgcct ggagctgttc aagttcacca tcggcatggg cgacctggag   2160
ttcactgaga actatgactt caaggctgtc ttcatcatcc tgctgctggc ctatgtaatt   2220
ctcacctaca tcctcctgct caacatgctc atcgccctca tgggtgagac tgtcaacaag   2280
atcgcacagg agagcaagaa catctggaag ctgcagagag ccatcaccat cctggacacg   2340
gagaagagct tccttaagtg catgaggaag gccttccgct caggcaagct gctgcaggtg   2400
gggtacacac ctgatggcaa ggacgactac cggtggtgct tcagggtgga cgaggtgaac   2460
tggaccacct ggaacaccaa cgtgggcatc atcaacgaag acccgggcaa ctgtgagggc   2520
gtcaagcgca ccctgagctt ctccctgcgg tcaagcagag tttcaggcag acactggaag   2580
aactttgccc tggtccccct tttaagagag gcaagtgctc gagataggca gtctgctcag   2640
cccgaggaag tttatctgcg acagttttca gggtctctga agccagagga cgctgaggtc   2700
ttcaagagtc ctgccgcttc cggggagaag tgaggacgtc acgcagacag cactgtcaac   2760
actgggcctt aggagacccc gttgccacgg ggggctgctg agggaacacc agtgctctgt   2820
cagcagcctg gcctggtctg tgcctgccca gcatgttccc aaatctgtgc tggacaagct   2880
gtgggaagcg ttcttggaag catggggagt gatgtacatc caaccgtcat tgtccccaag   2940
tgaatctcct aacagacttt caggttttta ctcactttac taaacagtgt ggatggtcag   3000
tctctactgg gacatgttag gcccttgttt tctttgattt tattcttttt tttgagacag   3060
aatttcactc ttctcgccca ggctggaatg cagtggcaca attttggctc cctgcaacct   3120
ccgcctcctg gattccagca attctcctgc ctcggcttcc caagtagctg ggattacagg   3180
cacgtgccac catgtctggc taattttttg tattttttta atagatatgg ggtttcgcca   3240
tgttggccag gctggtctcg aactcctgac ctcaggtgat ccgcccacct cggcctccca   3300
aagtgctggg attacaggtg tgagcctcca cacctggctg ttttctttga ttttattctt   3360
tttttttttt ttctgtgaga cagagtttca ctcttgttgc ccaggctgga gtgcagtggt   3420
gtgatcttgg ctcactgcaa cctctgcctc ccgggttcaa gcgattcttc tgcttcagtc   3480
tcccaagtag cttggattac aggtgagcac taccacgccc ggctaatttt tgtattttta   3540
atagagacgg ggtttcacca tgttggccag gctggtctcg aactcttgac ctcaggtgat   3600
ctgcccgcct tggcctccca aagtgctggg attacaggtg tgagccgctg cgctcggcct   3660
tctttgattt tatattatta ggagcaaaag taaatgaagc ccaggaaaac acctttggga   3720
acaaactctt cctttgatgg aaaatgcaga ggcccttcct ctctgtgccg tgcttgctcc   3780
tcttacctgc ccgggtggtt tgggggtgtt ggtgtttcct ccctggagaa gatgggggag   3840
gctgtcccac tcccagctct ggcagaatca agctgttgca gcagtgcctt cttcatcctt   3900
ccttacgatc aatcacagtc tccagaagat cagctcaatt gctgtgcagg ttaaaactac   3960
agaaccacat cccaaaggta cctggtaaga atgtttgaaa gatcttccat ttctaggaac   4020
cccagtcctg cttctccgca atggcacatg cttccactcc atccatactg gcatcctcaa   4080
ataaacagat atgtatwcat ataaaaaaaa aaaaaaaaaa aaaaaaaaac tcgagagtac   4140
ttctagagcg gccgcgggcc catcgatttt ccacccgggt ggggtaccag gtaaggtgcc   4200
aac                                                                 4203
<210> SEQ ID NO 2
<211> LENGTH: 4182
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 2
tgctagtgca gggcagctgc tgccagggcc gggcccggga ccccacggag gcggggagac     60
cactcttctc ccacacgagc ccagctctcc cttcgagtag caaccgcctt caagctcaca    120
agcacccgtg ggcctggggt gtgcctgcgt ctagctggtt gcacactggg ccacagagga    180
tccagcaagg atgaagaaat ggagcagcac agacttgggg gcagctgcgg acccactcca    240
aaaggacacc tgcccagacc ccctggatgg agaccctaac tccaggccac ctccagccaa    300
gccccagctc tccacggcca agagccgcac ccggctcttt gggaagggtg actcggagga    360
ggctttcccg gtggattgcc ctcacgagga aggtgagctg gactcctgcc cgaccatcac    420
agtcagccct gttatcacca tccagaggcc aggagacggc cccaccggtg ccaggctgct    480
gtcccaggac tctgtcgccg ccagcaccga gaagaccctc aggctctatg atcgcaggag    540
tatctttgaa gccgttgctc agaataactg ccaggatctg gagagcctgc tgctcttcct    600
gcagaagagc aagaagcacc tcacagacaa cgagttcaaa gaccctgaga cagggaagac    660
ctgtctgctg aaagccatgc tcaacctgca cgacggacag aacaccacca tccccctgct    720
cctggagatc gcgcggcaaa cggacagcct gaaggagctt gtcaacgcca gctacacgga    780
cagctactac aagggccaga cagcactgca catcgccatc gagagacgca acatggccct    840
ggtgaccctc ctggtggaga acggagcaga cgtccaggct gcggcccatg gggacttctt    900
taagaaaacc aaagggcggc ctggattcta cttcggtgaa ctgcccctgt ccctggccgc    960
gtgcaccaac cagctgggca tcgtgaagtt cctgctgcag aactcctggc agacggccga   1020
catcagcgcc agggactcgg tgggcaacac ggtgctgcac gccctggtgg aggtggccga   1080
caacacggcc gacaacacga agtttgtgac gagcatgtac aatgagattc tgatgctggg   1140
ggccaaactg cacccgacgc tgaagctgga ggagctcacc aacaagaagg gaatgacgcc   1200
gctggctctg gcagctggga ccgggaagat cggggtcttg gcctatattc tccagcggga   1260
gatccaggag cccgagtgca ggcacctgtc caggaagttc accgagtggg cctacgggcc   1320
cgtgcactcc tcgctgtacg acctgtcctg catcgacacc tgcgagaaga actcggtgct   1380
ggaggtgatc gcctacagca gcagcgagac ccctaatcgc cacgacatgc tcttggtgga   1440
gccgctgaac cgactcctgc aggacaagtg ggacagattc gtcaagcgca tcttctactt   1500
caacttcctg gtctactgcc tgtacatgat catcttcacc atggctgcct actacaggcc   1560
cgtggatggc ttgcctccct ttaagatgga aaaaattgga gactatttcc gagttactgg   1620
agagatcctg tctgtgttag gaggagtcta cttctttttc cgagggattc agtatttcct   1680
gcagaggcgg ccgtcgatga agaccctgtt tgtggacagc tacagtgaga tgcttttctt   1740
tctgcagtca ctgttcatgc tggccaccgt ggtgctgtac ttcagccacc tcaaggagta   1800
tgtggcttcc atggtattct ccctggcctt gggctggacc aacatgctct actacacccg   1860
cggtttccag cagatgggca tctatgccgt catgatagag aagatgatcc tgagagacct   1920
gtgccgtttc atgtttgtct acatcgtctt cttgttcggg ttttccacag cggtggtgac   1980
gctgattgaa gacgggaaga atgactccct gccgtctgag tccacgtcgc acaggtggcg   2040
ggggcctgcc tgcaggcccc ccgatagctc ctacaacagc ctgtactcca cctgcctgga   2100
gctgttcaag ttcaccatcg gcatgggcga cctggagttc actgagaact atgacttcaa   2160
ggctgtcttc atcatcctgc tgctggccta tgtaattctc acctacatcc tcctgctcaa   2220
catgctcatc gccctcatgg gtgagactgt caacaagatc gcacaggaga gcaagaacat   2280
ctggaagctg cagagagcca tcaccatcct ggacacggag aagagcttcc ttaagtgcat   2340
gaggaaggcc ttccgctcag gcaagctgct gcaggtgggg tacacacctg atggcaagga   2400
cgactaccgg tggtgcttca gggtggacga ggtgaactgg accacctgga acaccaacgt   2460
gggcatcatc aacgaagacc cgggcaactg tgagggcgtc aagcgcaccc tgagcttctc   2520
cctgcggtca agcagagttt caggcagaca ctggaagaac tttgccctgg tccccctttt   2580
aagagaggca agtgctcgag ataggcagtc tgctcagccc gaggaagttt atctgcgaca   2640
gttttcaggg tctctgaagc cagaggacgc tgaggtcttc aagagtcctg ccgcttccgg   2700
ggagaagtga ggacgtcacg cagacagcac tgtcaacact gggccttagg agaccccgtt   2760
gccacggggg gctgctgagg gaacaccagt gctctgtcag cagcctggcc tggtctgtgc   2820
ctgcccagca tgttcccaaa tctgtgctgg acaagctgtg ggaagcgttc ttggaagcat   2880
ggggagtgat gtacatccaa ccgtcactgt ccccaagtga atctcctaac agactttcag   2940
gtttttactc actttactaa acagtgtgga tggtcagtct ctactgggac atgttaggcc   3000
cttgttttct ttgattttat tctttttttt gagacagaat ttcactcttc tcgcccaggc   3060
tggaatgcag tggcacaatt ttggctccct gcaacctccg cctcctggat tccagcaatt   3120
ctcctgcctc ggcttcccaa gtagctggga ttacaggcac gtgccaccat gtctggctaa   3180
ttttttgtat ttttttaata gatatggggt ttcgccatgt tggccaggct ggtctcgaac   3240
tcctgacctc aggtgatccg cccacctcgg cctcccaaag tgctgggatt acaggtgtga   3300
gcctccacac ctggctgttt tctttgattt tattcttttt ttttttttct gtgagacaga   3360
gtttcactct tgttgcccag gctggagtgc agtggtgtga tcttggctca ctgcaacctc   3420
tgcctcccgg gttcaagcga ttcttctgct tcagtctccc aagtagcttg gattacaggt   3480
gagcactacc acgcccggct aatttttgta tttttaatag agacggggtt tcaccatgtt   3540
ggccaggctg gtctcgaact cttgacctcg ggtgatctgc ccgccttggc ctcccaaagt   3600
gctgggatta caggtgtgag ccgctgcgct cggccttctt tgattttata ttattaggag   3660
caaaagtaaa tgaagcccag gaaaacacct ttgggaacaa actcttcctt tgatggaaaa   3720
tgcagaggcc cttcctctct gtgccgtgct tgctcctctt acctgcccgg gtggtttggg   3780
ggtgttggtg tttcctccct ggagaagatg ggggaggctg tcccactccc agctctggca   3840
gaatcaagct gttgcagcag tgccttcttc atccttcctt acgatcaatc acagtctcca   3900
gaagatcagc tcaattgctg tgcaggttaa aactacagaa ccacatccca aaggtacctg   3960
gtaagaatgt ttgaaagatc ttccatttct aggaacccca gtcctgcttc tccgcaatgg   4020
cacatgcttc cactccatcc atactggcat cctcaaataa acagatatgt atacatataa   4080
aaaaaaaaaa aaaaaaaaaa aaaaactcga gagtacttct agagcggccg cgggcccatc   4140
gattttccac ccgggtgggg taccaggtaa gtgtacccaa tc                      4182
<210> SEQ ID NO 3
<211> LENGTH: 4171
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 3
gcagagtgtg cagtatagat tcagcgtttg tcgactgact gaatgatagc acaatccagg     60
ctgcttcctg ttggctgggt ttggttggac tgggacccgt cagaggaaaa ggcaacgccg    120
ctgacaaaga acattgccga aaggttcatg ggaggctccg gctaacaggt tgcacactgg    180
gccacagagg atccagcaag gatgaagaaa tggagcagca cagacttggg ggcagctgcg    240
gacccactcc aaaaggacac ctgcccagac cccctggatg gagaccctaa ctccaggcca    300
cctccagcca agccccagct ctccacggcc aagagccgca cccggctctt tgggaagggt    360
gactcggagg aggctttccc ggtggattgc cctcacgagg aaggtgagct ggactcctgc    420
ccgaccatca cagtcagccc tgttatcacc atccagaggc caggagacgg ctccaccggt    480
gccaggctgc tgtcccagga ctctgtcgcc gccagcaccg agaagaccct caggctctat    540
gatcgcagga gtatctttga agccgttgct cagaataact gccaggatct ggagagcctg    600
ctgctcttcc tgcagaagag caagaagcac ctcacagaca acgagttcaa agaccctgag    660
acagggaaga cctgtctgct gaaagccatg ctcaacctgc atgacggaca gaacaccacc    720
atccccctgc tcctggagat cgcgcggcaa acggacagcc tgaaggagct tgtcaacgcc    780
agctacacgg acagctacta caagggccag acagcactgc acatcgccat cgagagacgc    840
aacatggccc tggtgaccct cctggtggag aacggagcag acgtccaggc tgcggcccat    900
ggggacttct ttaagaaaac caaagggcgg cctggattct acttcggtga actgcccctg    960
tccctggccg cgtgcaccaa ccagctgggc atcgtgaagt tcctgctgca gaactcctgg   1020
cagacggccg acatcagcgc cagggactcg gtgggcaaca cggtgctgca cgccctggtg   1080
gaggtggccg acaacacggc cgacaacacg aagtttgtga cgagcatgta caatgagatt   1140
ctgatcctgg gggccaaact gcacccgacg ctgaagctgg aggagctcac caacaagaag   1200
ggaatgacgc cgctggctct ggcagctggg accgggaaga tcggggtctt ggcctatatt   1260
ctccagcggg agatccagga gcccgagtgc aggcacctgt ccaggaagtt caccgagtgg   1320
gcctacgggc ccgtgcactc ctcgctgtac gacctgtcct gcatcgacac ctgcgagaag   1380
aactcggtgc tggaggtgat cgcctacagc agcagcgaga cccctaatcg ccacgacatg   1440
ctcttggtgg agccgctgaa ccgactcctg caggacaagt gggacagatt cgtcaagcgc   1500
atcttctact tcaacttcct ggtctactgc ctgtacatga tcatcttcac catggctgcc   1560
tactacaggc ccgtggatgg cttgcctccc tttaagatgg aaaaaattgg agactatttc   1620
cgagttactg gagagatcct gtctgtgtta ggaggagtct acttcttttt ccgagggatt   1680
cagtatttcc tgcaggcggc cgtcgatgaa gaccctgttt gtggacagct acagtgagat   1740
gcttttcttt ctgcagtcac tgttcatgct ggccaccgtg gtgctgtact tcagccacct   1800
caaggagtat gtggcttcca tggtattctc cctggccttg ggctggacca acatgctcta   1860
ctacacccgc ggtttccagc agatgggcat ctatgccgtc atgatagaga agatgatcct   1920
gagagacctg tgccgtttca tgtttgtcta catcgtcttc ttgttcgggt tttccacagc   1980
ggtggtgacg ctgattgaag acgggaagaa tgactccctg ccgtctgagt ccacgtcgca   2040
caggtggcgg gggcctgcct gcaggccccc cgatagctcc tacaacagcc tgtactccac   2100
ctgcctggag ctgttcaagt tcaccatcgg catgggcgac ctggagttca ctgagaacta   2160
tgacttcaag gctgtcttca tcatcctgct gctggcctat gtaattctca cctacatcct   2220
cctgctcaac atgctcatcg ccctcatggg tgagactgtc aacaagatcg cacaggagag   2280
caagaacatc tggaagctgc agagagccat caccatcctg gacacggaga agagcttcct   2340
taagtgcatg aggaaggcct tccgctcagg caagctgctg caggtggggt acacacctga   2400
tggcaaggac gactaccggt ggtgcttcag ggtggacgag gtgaactgga ccacctggaa   2460
caccaacgtg ggcatcatca acgaagaccc gggcaactgt gagggcgtca agcgcaccct   2520
gagcttctcc ctgcggtcaa gcagagtttc aggcagacac tggaagaact ttgccctggt   2580
ccccctttta agagaggcaa gtgctcgaga taggcagtct gctcagcccg aggaagttta   2640
tctgcgacag ttttcagggt ctctgaagcc agaggacgct gaggtcttca agagtcctgc   2700
cgcttccggg gagaagtgag gacgtcacgc agacagcact gtcaacactg ggccttagga   2760
gaccccgttg ccacgggggg ctgctgaggg aacaccagtg ctctgtcagc agcctggcct   2820
ggtctgtgcc tgcccagcat gttcccaaat ctgtgctgga caagctgtgg gaagcgttct   2880
tggaagcatg gggagtgatg tacatccaac cgtcactgtc cccaagtgaa tctcctaaca   2940
gactttcagg tttttactca ctttactaaa cagtttggat ggtcagtctc tactgggaca   3000
tgttaggccc ttgttttctt tgattttatt cttttttttg agacagaatt tcactcttct   3060
cacccaggct ggaatgcagt ggcacaattt tggctccctg caacctccgc ctcctggatt   3120
ccagcaattc tcctgcctcg gcttcccaag tagctgggat tacaggcacg tgccaccatg   3180
tctggctaat tttttgtatt tttttaatag atatggggtt tcgccatgtt ggccaggctg   3240
gtctcgaact cctgacctca ggtgatccgc ccacctcggc ctcccaaagt gctgggatta   3300
caggtgtgag cctccacacc tggctgtttt ctttgatttt attctttttt tttttttctg   3360
tgagacagag tttcactctt gttgcccagg ctggagtgca gtggtgtgat cttggctcac   3420
tgcaacctct gcctcccggg ttcaagcgat tcttctgctt cagtctccca agtagcttgg   3480
attacaggtg agcactacca cgcccggcta atttttgtat ttttaataga gacggggttt   3540
caccatgttg gccaggctgg tctcgaactc ttgacctcag gtgatctgcc cgccttggcc   3600
tcccaaagtg ctgggattac aggtgtgagc tgctgcgctc ggccttcttt gattttatat   3660
tattaggagc aaaagtaaat gaagcccagg aaaacacctt tgggaacaaa ctcttccttt   3720
gatggaaaat gcagaggccc ttcctctctg tgccgtgctt gctcctctta cctgcccggg   3780
tggtttgggg gtgttggtgt ttcctccctg gagaagatgg gggaggctgt cccactccca   3840
gctctggcag aatcaagctg ttgcagcagt gccttcttca tccttcctta cgatcaatca   3900
cagtctccag aagatcagct caattgctgt gcaggttaaa actacagaac cacatcccaa   3960
aggtacctgg taagaatgtt tgaaagatct tccatttcta ggaaccccag tcctgcttct   4020
ccgcaatggc acatgcttcc actccatcca tactggcatc ctcaaataaa cagatatgta   4080
tacataaaaa aaaaaaaaaa aaactcgaga gtacttctag agcggccgcg ggcccatcga   4140
ttttccaccc gggtggggta ccaggtaagt g                                  4171
<210> SEQ ID NO 4
<211> LENGTH: 839
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: TRANSMEM
<222> LOCATION: (434)..(455)
<223> OTHER INFORMATION: TM1
<221> NAME/KEY: TRANSMEM
<222> LOCATION: (480)..(495)
<223> OTHER INFORMATION: TM2
<221> NAME/KEY: TRANSMEM
<222> LOCATION: (510)..(530)
<223> OTHER INFORMATION: TM3
<221> NAME/KEY: TRANSMEM
<222> LOCATION: (543)..(569)
<223> OTHER INFORMATION: TM4
<221> NAME/KEY: TRANSMEM
<222> LOCATION: (577)..(596)
<223> OTHER INFORMATION: TM5
<221> NAME/KEY: TRANSMEM
<222> LOCATION: (656)..(684)
<223> OTHER INFORMATION: TM6
<400> SEQUENCE: 4
Met Lys Lys Trp Ser Ser Thr Asp Leu Gly Ala Ala Ala Asp Pro Leu
1               5                  10                  15
Gln Lys Asp Thr Cys Pro Asp Pro Leu Asp Gly Asp Pro Asn Ser Arg
20                  25                  30
Pro Pro Pro Ala Lys Pro Gln Leu Ser Thr Ala Lys Ser Arg Thr Arg
35                  40                  45
Leu Phe Gly Lys Gly Asp Ser Glu Glu Ala Phe Pro Val Asp Cys Pro
50                  55                  60
His Glu Glu Gly Glu Leu Asp Ser Cys Pro Thr Ile Thr Val Ser Pro
65                  70                  75                  80
Val Ile Thr Ile Gln Arg Pro Gly Asp Gly Pro Thr Gly Ala Arg Leu
85                  90                  95
Leu Ser Gln Asp Ser Val Ala Ala Ser Thr Glu Lys Thr Leu Arg Leu
100                 105                 110
Tyr Asp Arg Arg Ser Ile Phe Glu Ala Val Ala Gln Asn Asn Cys Gln
115                 120                 125
Asp Leu Glu Ser Leu Leu Leu Phe Leu Gln Lys Ser Lys Lys His Leu
130                 135                 140
Thr Asp Asn Glu Phe Lys Asp Pro Glu Thr Gly Lys Thr Cys Leu Leu
145                 150                 155                 160
Lys Ala Met Leu Asn Leu His Asp Gly Gln Asn Thr Thr Ile Pro Leu
165                 170                 175
Leu Leu Glu Ile Ala Arg Gln Thr Asp Ser Leu Lys Glu Leu Val Asn
180                 185                 190
Ala Ser Tyr Thr Asp Ser Tyr Tyr Lys Gly Gln Thr Ala Leu His Ile
195                 200                 205
Ala Ile Glu Arg Arg Asn Met Ala Leu Val Thr Leu Leu Val Glu Asn
210                 215                 220
Gly Ala Asp Val Gln Ala Ala Ala His Gly Asp Phe Phe Lys Lys Thr
225                 230                 235                 240
Lys Gly Arg Pro Gly Phe Tyr Phe Gly Glu Leu Pro Leu Ser Leu Ala
245                 250                 255
Ala Cys Thr Asn Gln Leu Gly Ile Val Lys Phe Leu Leu Gln Asn Ser
260                 265                 270
Trp Gln Thr Ala Asp Ile Ser Ala Arg Asp Ser Val Gly Asn Thr Val
275                 280                 285
Leu His Ala Leu Val Glu Val Ala Asp Asn Thr Ala Asp Asn Thr Lys
290                 295                 300
Phe Val Thr Ser Met Tyr Asn Glu Ile Leu Met Leu Gly Ala Lys Leu
305                 310                 315                 320
His Pro Thr Leu Lys Leu Glu Glu Leu Thr Asn Lys Lys Gly Met Thr
325                 330                 335
Pro Leu Ala Leu Ala Ala Gly Thr Gly Lys Ile Gly Val Leu Ala Tyr
340                 345                 350
Ile Leu Gln Arg Glu Ile Gln Glu Pro Glu Cys Arg His Leu Ser Arg
355                 360                 365
Lys Phe Thr Glu Trp Ala Tyr Gly Pro Val His Ser Ser Leu Tyr Asp
370                 375                 380
Leu Ser Cys Ile Asp Thr Cys Glu Lys Asn Ser Val Leu Glu Val Ile
385                 390                 395                 400
Ala Tyr Ser Ser Ser Glu Thr Pro Asn Arg His Asp Met Leu Leu Val
405                 410                 415
Glu Pro Leu Asn Arg Leu Leu Gln Asp Lys Trp Asp Arg Phe Val Lys
420                 425                 430
Arg Ile Phe Tyr Phe Asn Phe Leu Val Tyr Cys Leu Tyr Met Ile Ile
435                 440                 445
Phe Thr Met Ala Ala Tyr Tyr Arg Pro Val Asp Gly Leu Pro Pro Phe
450                 455                 460
Lys Met Glu Lys Ile Gly Asp Tyr Phe Arg Val Thr Gly Glu Ile Leu
465                 470                 475                 480
Ser Val Leu Gly Gly Val Tyr Phe Phe Phe Arg Gly Ile Gln Tyr Phe
485                 490                 495
Leu Gln Arg Arg Pro Ser Met Lys Thr Leu Phe Val Asp Ser Tyr Ser
500                 505                 510
Glu Met Leu Phe Phe Leu Gln Ser Leu Phe Met Leu Ala Thr Val Val
515                 520                 525
Leu Tyr Phe Ser His Leu Lys Glu Tyr Val Ala Ser Met Val Phe Ser
530                 535                 540
Leu Ala Leu Gly Trp Thr Asn Met Leu Tyr Tyr Thr Arg Gly Phe Gln
545                 550                 555                 560
Gln Met Gly Ile Tyr Ala Val Met Ile Glu Lys Met Ile Leu Arg Asp
565                 570                 575
Leu Cys Arg Phe Met Phe Val Tyr Ile Val Phe Leu Phe Gly Phe Ser
580                 585                 590
Thr Ala Val Val Thr Leu Ile Glu Asp Gly Lys Asn Asp Ser Leu Pro
595                 600                 605
Ser Glu Ser Thr Ser His Arg Trp Arg Gly Pro Ala Cys Arg Pro Pro
610                 615                 620
Asp Ser Ser Tyr Asn Ser Leu Tyr Ser Thr Cys Leu Glu Leu Phe Lys
625                 630                 635                 640
Phe Thr Ile Gly Met Gly Asp Leu Glu Phe Thr Glu Asn Tyr Asp Phe
645                 650                 655
Lys Ala Val Phe Ile Ile Leu Leu Leu Ala Tyr Val Ile Leu Thr Tyr
660                 665                 670
Ile Leu Leu Leu Asn Met Leu Ile Ala Leu Met Gly Glu Thr Val Asn
675                 680                 685
Lys Ile Ala Gln Glu Ser Lys Asn Ile Trp Lys Leu Gln Arg Ala Ile
690                 695                 700
Thr Ile Leu Asp Thr Glu Lys Ser Phe Leu Lys Cys Met Arg Lys Ala
705                 710                 715                 720
Phe Arg Ser Gly Lys Leu Leu Gln Val Gly Tyr Thr Pro Asp Gly Lys
725                 730                 735
Asp Asp Tyr Arg Trp Cys Phe Arg Val Asp Glu Val Asn Trp Thr Thr
740                 745                 750
Trp Asn Thr Asn Val Gly Ile Ile Asn Glu Asp Pro Gly Asn Cys Glu
755                 760                 765
Gly Val Lys Arg Thr Leu Ser Phe Ser Leu Arg Ser Ser Arg Val Ser
770                 775                 780
Gly Arg His Trp Lys Asn Phe Ala Leu Val Pro Leu Leu Arg Glu Ala
785                 790                 795                 800
Ser Ala Arg Asp Arg Gln Ser Ala Gln Pro Glu Glu Val Tyr Leu Arg
805                 810                 815
Gln Phe Ser Gly Ser Leu Lys Pro Glu Asp Ala Glu Val Phe Lys Ser
820                 825                 830
Pro Ala Ala Ser Gly Glu Lys
835
<210> SEQ ID NO 5
<211> LENGTH: 511
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: TRANSMEM
<222> LOCATION: (434)..(455)
<223> OTHER INFORMATION: TM1
<221> NAME/KEY: TRANSMEM
<222> LOCATION: (480)..(495)
<223> OTHER INFORMATION: TM2
<400> SEQUENCE: 5
Met Lys Lys Trp Ser Ser Thr Asp Leu Gly Ala Ala Ala Asp Pro Leu
1               5                  10                  15
Gln Lys Asp Thr Cys Pro Asp Pro Leu Asp Gly Asp Pro Asn Ser Arg
20                  25                  30
Pro Pro Pro Ala Lys Pro Gln Leu Ser Thr Ala Lys Ser Arg Thr Arg
35                  40                  45
Leu Phe Gly Lys Gly Asp Ser Glu Glu Ala Phe Pro Val Asp Cys Pro
50                  55                  60
His Glu Glu Gly Glu Leu Asp Ser Cys Pro Thr Ile Thr Val Ser Pro
65                  70                  75                  80
Val Ile Thr Ile Gln Arg Pro Gly Asp Gly Ser Thr Gly Ala Arg Leu
85                  90                  95
Leu Ser Gln Asp Ser Val Ala Ala Ser Thr Glu Lys Thr Leu Arg Leu
100                 105                 110
Tyr Asp Arg Arg Ser Ile Phe Glu Ala Val Ala Gln Asn Asn Cys Gln
115                 120                 125
Asp Leu Glu Ser Leu Leu Leu Phe Leu Gln Lys Ser Lys Lys His Leu
130                 135                 140
Thr Asp Asn Glu Phe Lys Asp Pro Glu Thr Gly Lys Thr Cys Leu Leu
145                 150                 155                 160
Lys Ala Met Leu Asn Leu His Asp Gly Gln Asn Thr Thr Ile Pro Leu
165                 170                 175
Leu Leu Glu Ile Ala Arg Gln Thr Asp Ser Leu Lys Glu Leu Val Asn
180                 185                 190
Ala Ser Tyr Thr Asp Ser Tyr Tyr Lys Gly Gln Thr Ala Leu His Ile
195                 200                 205
Ala Ile Glu Arg Arg Asn Met Ala Leu Val Thr Leu Leu Val Glu Asn
210                 215                 220
Gly Ala Asp Val Gln Ala Ala Ala His Gly Asp Phe Phe Lys Lys Thr
225                 230                 235                 240
Lys Gly Arg Pro Gly Phe Tyr Phe Gly Glu Leu Pro Leu Ser Leu Ala
245                 250                 255
Ala Cys Thr Asn Gln Leu Gly Ile Val Lys Phe Leu Leu Gln Asn Ser
260                 265                 270
Trp Gln Thr Ala Asp Ile Ser Ala Arg Asp Ser Val Gly Asn Thr Val
275                 280                 285
Leu His Ala Leu Val Glu Val Ala Asp Asn Thr Ala Asp Asn Thr Lys
290                 295                 300
Phe Val Thr Ser Met Tyr Asn Glu Ile Leu Ile Leu Gly Ala Lys Leu
305                 310                 315                 320
His Pro Thr Leu Lys Leu Glu Glu Leu Thr Asn Lys Lys Gly Met Thr
325                 330                 335
Pro Leu Ala Leu Ala Ala Gly Thr Gly Lys Ile Gly Val Leu Ala Tyr
340                 345                 350
Ile Leu Gln Arg Glu Ile Gln Glu Pro Glu Cys Arg His Leu Ser Arg
355                 360                 365
Lys Phe Thr Glu Trp Ala Tyr Gly Pro Val His Ser Ser Leu Tyr Asp
370                 375                 380
Leu Ser Cys Ile Asp Thr Cys Glu Lys Asn Ser Val Leu Glu Val Ile
385                 390                 395                 400
Ala Tyr Ser Ser Ser Glu Thr Pro Asn Arg His Asp Met Leu Leu Val
405                 410                 415
Glu Pro Leu Asn Arg Leu Leu Gln Asp Lys Trp Asp Arg Phe Val Lys
420                 425                 430
Arg Ile Phe Tyr Phe Asn Phe Leu Val Tyr Cys Leu Tyr Met Ile Ile
435                 440                 445
Phe Thr Met Ala Ala Tyr Tyr Arg Pro Val Asp Gly Leu Pro Pro Phe
450                 455                 460
Lys Met Glu Lys Ile Gly Asp Tyr Phe Arg Val Thr Gly Glu Ile Leu
465                 470                 475                 480
Ser Val Leu Gly Gly Val Tyr Phe Phe Phe Arg Gly Ile Gln Tyr Phe
485                 490                 495
Leu Gln Ala Ala Val Asp Glu Asp Pro Val Cys Gly Gln Leu Gln
500                 505                 510
<210> SEQ ID NO 6
<211> LENGTH: 24
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:H-FLAG epitope
<400> SEQUENCE: 6
Ala Ser Pro Thr Tyr Arg Leu Tyr Ser Ala Ser Pro Ala Ser Pro Ala
1               5                  10                  15
Ser Pro Ala Ser Pro Leu Tyr Ser
20
<210> SEQ ID NO 7
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:His6x epitope
<400> SEQUENCE: 7
His His His His His His
1               5
<210> SEQ ID NO 8
<211> LENGTH: 2633
<212> TYPE: DNA
<213> ORGANISM: Rattus sp.
<300> PUBLICATION INFORMATION:
<301> AUTHORS: Caterina, Michael J.
Schumacher, Mark A.
Tominaga, Makoto
Rosen, Tobias A.
Levine, Jon D.
Julius, David
<302> TITLE: The capsaicin receptor: a heat-activated ion channel in
the pain pathway
<303> JOURNAL: Nature
<304> VOLUME: 389
<306> PAGES: 816-824
<307> DATE: 1997
<400> SEQUENCE: 8
ctggaaagga tggaacaacg ggctagctta gactcagagg agtctgagtc cccaccccaa     60
gagaactcct gcctggaccc tccagacaga gaccctaact gcaagccacc tccagtcaag    120
ccccacatct tcactaccag gagtcgtacc cggctttttg ggaagggtga ctcggaggag    180
gcctctcccc tggactgccc ttatgaggaa ggcgggctgg cttcctgccc tatcatcact    240
gtcagctctg ttctaactat ccagaggcct ggggatggac ctgccagtgt caggccgtca    300
tcccaggact ccgtctccgc tggtgagaag cccccgaggc tctatgatcg caggagcatc    360
ttcgatgctg tggctcagag taactgccag gagctggaga gcctgctgcc cttcctgcag    420
aggagcaaga agcgcctgac tgacagcgag ttcaaagacc cagagacagg aaagacctgt    480
ctgctaaaag ccatgctcaa tctgcacaat gggcagaatg acaccatcgc tctgctcctg    540
gacgttgccc ggaagacaga cagcctgaag cagtttgtca atgccagcta cacagacagc    600
tactacaagg gccagacagc actgcacatt gccattgaac ggcggaacat gacgctggtg    660
accctcttgg tggagaatgg agcagatgtc caggctgcgg ctaacgggga cttcttcaag    720
aaaaccaaag ggaggcctgg cttctacttt ggtgagctgc ccctgtccct ggctgcgtgc    780
accaaccagc tggccattgt gaagttcctg ctgcagaact cctggcagcc tgcagacatc    840
agcgcccggg actcagtggg caacacggtg cttcatgccc tggtggaggt ggcagataac    900
acagttgaca acaccaagtt cgtgacaagc atgtacaacg agatcttgat cctgggggcc    960
aaactccacc ccacgctgaa gctggaagag atcaccaaca ggaaggggct cacgccactg   1020
gctctggctg ctagcagtgg gaagatcggg gtcttggcct acattctcca gagggagatc   1080
catgaacccg agtgccgaca cctatccagg aagttcaccg aatgggccta tgggccagtg   1140
cactcctccc tttatgacct gtcctgcatt gacacctgtg aaaagaactc ggttctggag   1200
gtgatcgctt acagcagcag tgagacccct aaccgtcatg acatgcttct cgtggaaccc   1260
ttgaaccgac tcctacagga caagtgggac agatttgtca agcgcatctt ctacttcaac   1320
ttcttcgtct actgcttgta tatgatcatc ttcaccgcgg ctgcctacta tcggcctgtg   1380
gaaggcttgc ccccctataa gctgaaaaac accgttgggg actatttccg agtcaccgga   1440
gagatcttgt ctgtgtcagg aggagtctac ttcttcttcc gagggattca atatttcctg   1500
cagaggcgac catccctcaa gagtttgttt gtggacagct acagtgagat acttttcttt   1560
gtacagtcgc tgttcatgct ggtgtctgtg gtactgtact tcagccaacg caaggagtat   1620
gtggcttcca tggtgttctc cctggccatg ggctggacca acatgctcta ctatacccga   1680
ggattccagc agatgggcat ctatgctgtc atgattgaga agatgatcct cagagacctg   1740
tgccggttta tgttcgtcta cctcgtgttc ttgtttggat tttccacagc tgtggtgaca   1800
ctgattgagg atgggaagaa taactctctg cctatggagt ccacaccaca caagtgccgg   1860
gggtctgcct gcaagccagg taactcttac aacagcctgt attccacatg tctggagctg   1920
ttcaagttca ccatcggcat gggcgacctg gagttcactg agaactacga cttcaaggct   1980
gtcttcatca tcctgttact ggcctatgtg attctcacct acatccttct gctcaacatg   2040
ctcattgctc tcatgggtga gaccgtcaac aagattgcac aagagagcaa gaacatctgg   2100
aagctgcaga gagccatcac catcctggat acagagaaga gcttcctgaa gtgcatgagg   2160
aaggccttcc gctctggcaa gctgctgcag gtggggttca ctcctgacgg caaggatgac   2220
taccggtggt gtttcagggt ggacgaggta aactggacta cctggaacac caatgtgggt   2280
atcatcaacg aggacccagg caactgtgag ggcgtcaagc gcaccctgag cttctccctg   2340
aggtcaggcc gagtttcagg gagaaactgg aagaactttg ccctggttcc ccttctgagg   2400
gatgcaagca ctcgagatag acatgccacc cagcaggaag aagttcaact gaagcattat   2460
acgggatccc ttaagccaga ggatgctgag gttttcaagg attccatggt cccaggggag   2520
aaataatgga cactatgcag ggatcaatgc ggggtctttg ggtggtctgc ttagggaacc   2580
agcagggttg acgttatctg ggtccactct gtgcctgcct aggcacattc cta          2633
<210> SEQ ID NO 9
<211> LENGTH: 838
<212> TYPE: PRT
<213> ORGANISM: Rattus sp.
<300> PUBLICATION INFORMATION:
<301> AUTHORS: Caterina, Michael J.
Schumacher, Mark A.
Tominaga, Makoto
Rosen, Tobias A.
<302> TITLE: The capsaicin receptor: a heat-activated ion channel in
the pain pathway
<303> JOURNAL: Nature
<304> VOLUME: 389
<306> PAGES: 816-824
<307> DATE: 1997
<400> SEQUENCE: 9
Met Glu Gln Arg Ala Ser Leu Asp Ser Glu Glu Ser Glu Ser Pro Pro
1               5                  10                  15
Gln Glu Asn Ser Cys Leu Asp Pro Pro Asp Arg Asp Pro Asn Cys Lys
20                  25                  30
Pro Pro Pro Val Lys Pro His Ile Phe Thr Thr Arg Ser Arg Thr Arg
35                  40                  45
Leu Phe Gly Lys Gly Asp Ser Glu Glu Ala Ser Pro Leu Asp Cys Pro
50                  55                  60
Tyr Glu Glu Gly Gly Leu Ala Ser Cys Pro Ile Ile Thr Val Ser Ser
65                  70                  75                  80
Val Leu Thr Ile Gln Arg Pro Gly Asp Gly Pro Ala Ser Val Arg Pro
85                  90                  95
Ser Ser Gln Asp Ser Val Ser Ala Gly Glu Lys Pro Pro Arg Leu Tyr
100                 105                 110
Asp Arg Arg Ser Ile Phe Asp Ala Val Ala Gln Ser Asn Cys Gln Glu
115                 120                 125
Leu Glu Ser Leu Leu Pro Phe Leu Gln Arg Ser Lys Lys Arg Leu Thr
130                 135                 140
Asp Ser Glu Phe Lys Asp Pro Glu Thr Gly Lys Thr Cys Leu Leu Lys
145                 150                 155                 160
Ala Met Leu Asn Leu His Asn Gly Gln Asn Asp Thr Ile Ala Leu Leu
165                 170                 175
Leu Asp Val Ala Arg Lys Thr Asp Ser Leu Lys Gln Phe Val Asn Ala
180                 185                 190
Ser Tyr Thr Asp Ser Tyr Tyr Lys Gly Gln Thr Ala Leu His Ile Ala
195                 200                 205
Ile Glu Arg Arg Asn Met Thr Leu Val Thr Leu Leu Val Glu Asn Gly
210                 215                 220
Ala Asp Val Gln Ala Ala Ala Asn Gly Asp Phe Phe Lys Lys Thr Lys
225                 230                 235                 240
Gly Arg Pro Gly Phe Tyr Phe Gly Glu Leu Pro Leu Ser Leu Ala Ala
245                 250                 255
Cys Thr Asn Gln Leu Ala Ile Val Lys Phe Leu Leu Gln Asn Ser Trp
260                 265                 270
Gln Pro Ala Asp Ile Ser Ala Arg Asp Ser Val Gly Asn Thr Val Leu
275                 280                 285
His Ala Leu Val Glu Val Ala Asp Asn Thr Val Asp Asn Thr Lys Phe
290                 295                 300
Val Thr Ser Met Tyr Asn Glu Ile Leu Ile Leu Gly Ala Lys Leu His
305                 310                 315                 320
Pro Thr Leu Lys Leu Glu Glu Ile Thr Asn Arg Lys Gly Leu Thr Pro
325                 330                 335
Leu Ala Leu Ala Ala Ser Ser Gly Lys Ile Gly Val Leu Ala Tyr Ile
340                 345                 350
Leu Gln Arg Glu Ile His Glu Pro Glu Cys Arg His Leu Ser Arg Lys
355                 360                 365
Phe Thr Glu Trp Ala Tyr Gly Pro Val His Ser Ser Leu Tyr Asp Leu
370                 375                 380
Ser Cys Ile Asp Thr Cys Glu Lys Asn Ser Val Leu Glu Val Ile Ala
385                 390                 395                 400
Tyr Ser Ser Ser Glu Thr Pro Asn Arg His Asp Met Leu Leu Val Glu
405                 410                 415
Pro Leu Asn Arg Leu Leu Gln Asp Lys Trp Asp Arg Phe Val Lys Arg
420                 425                 430
Ile Phe Tyr Phe Asn Phe Phe Val Tyr Cys Leu Tyr Met Ile Ile Phe
435                 440                 445
Thr Ala Ala Ala Tyr Tyr Arg Pro Val Glu Gly Leu Pro Pro Tyr Lys
450                 455                 460
Leu Lys Asn Thr Val Gly Asp Tyr Phe Arg Val Thr Gly Glu Ile Leu
465                 470                 475                 480
Ser Val Ser Gly Gly Val Tyr Phe Phe Phe Arg Gly Ile Gln Tyr Phe
485                 490                 495
Leu Gln Arg Arg Pro Ser Leu Lys Ser Leu Phe Val Asp Ser Tyr Ser
500                 505                 510
Glu Ile Leu Phe Phe Val Gln Ser Leu Phe Met Leu Val Ser Val Val
515                 520                 525
Leu Tyr Phe Ser Gln Arg Lys Glu Tyr Val Ala Ser Met Val Phe Ser
530                 535                 540
Leu Ala Met Gly Trp Thr Asn Met Leu Tyr Tyr Thr Arg Gly Phe Gln
545                 550                 555                 560
Gln Met Gly Ile Tyr Ala Val Met Ile Glu Lys Met Ile Leu Arg Asp
565                 570                 575
Leu Cys Arg Phe Met Phe Val Tyr Leu Val Phe Leu Phe Gly Phe Ser
580                 585                 590
Thr Ala Val Val Thr Leu Ile Glu Asp Gly Lys Asn Asn Ser Leu Pro
595                 600                 605
Met Glu Ser Thr Pro His Lys Cys Arg Gly Ser Ala Cys Lys Pro Gly
610                 615                 620
Asn Ser Tyr Asn Ser Leu Tyr Ser Thr Cys Leu Glu Leu Phe Lys Phe
625                 630                 635                 640
Thr Ile Gly Met Gly Asp Leu Glu Phe Thr Glu Asn Tyr Asp Phe Lys
645                 650                 655
Ala Val Phe Ile Ile Leu Leu Leu Ala Tyr Val Ile Leu Thr Tyr Ile
660                 665                 670
Leu Leu Leu Asn Met Leu Ile Ala Leu Met Gly Glu Thr Val Asn Lys
675                 680                 685
Ile Ala Gln Glu Ser Lys Asn Ile Trp Lys Leu Gln Arg Ala Ile Thr
690                 695                 700
Ile Leu Asp Thr Glu Lys Ser Phe Leu Lys Cys Met Arg Lys Ala Phe
705                 710                 715                 720
Arg Ser Gly Lys Leu Leu Gln Val Gly Phe Thr Pro Asp Gly Lys Asp
725                 730                 735
Asp Tyr Arg Trp Cys Phe Arg Val Asp Glu Val Asn Trp Thr Thr Trp
740                 745                 750
Asn Thr Asn Val Gly Ile Ile Asn Glu Asp Pro Gly Asn Cys Glu Gly
755                 760                 765
Val Lys Arg Thr Leu Ser Phe Ser Leu Arg Ser Gly Arg Val Ser Gly
770                 775                 780
Arg Asn Trp Lys Asn Phe Ala Leu Val Pro Leu Leu Arg Asp Ala Ser
785                 790                 795                 800
Thr Arg Asp Arg His Ala Thr Gln Gln Glu Glu Val Gln Leu Lys His
805                 810                 815
Tyr Thr Gly Ser Leu Lys Pro Glu Asp Ala Glu Val Phe Lys Asp Ser
820                 825                 830
Met Val Pro Gly Glu Lys
835
<210> SEQ ID NO 10
<211> LENGTH: 502
<212> TYPE: DNA
<213> ORGANISM: Rattus sp.
<400> SEQUENCE: 10
agatcttgat cctgggggcc aaactccacc ccacgctgaa gctggaagag atcaccaaca     60
ggaaggggct cacgccactg gctctggctg ctagcagtgg gaagatcggg gtcttggcct    120
acattctcca gagggagatc catgaacccg agtgccgaca cctatccagg aagttcaccg    180
aatgggccta tgggccagtg cactcctccc tttatgacct gtcctgcatt gacacctgtg    240
aaaagaactc ggttctggag gtgatcgctt acagcagcag tgagacccct aaccgtcatg    300
acatgcttct cgtggaaccc ttgaaccgac tcctacagga caagtgggac agatttgtca    360
agcgcatctt ctacttcaac ttcttcgtct actgcttgta tatgatcatc ttcaccgcgg    420
ctgcctacta tcggcctgtg gaaggcttgc ccccctataa gctgaaaaac accgttgggg    480
actatttccg agtcaccgga ga                                             502
<210> SEQ ID NO 11
<211> LENGTH: 819
<212> TYPE: DNA
<213> ORGANISM: Rattus sp.
<400> SEQUENCE: 11
ccatgggctg gaccaacatg ctctactata cccgaggatt ccagcagatg ggcatctatg     60
ctgtcatgat tgagaagatg atcctcagag acctgtgccg gtttatgttc gtctacctcg    120
tgttcttgtt tggattttcc acagctgtgg tgacactgat tgaggatggg aagaataact    180
ctctgcctat ggagtccaca ccacacaagt gccgggggtc tgcctgcaag ccaggtaact    240
cttacaacag cctgtattcc acatgtctgg agctgttcaa gttcaccatc ggcatgggcg    300
acctggagtt cactgagaac tacgacttca aggctgtctt catcatcctg ttactggcct    360
atgtgattct cacctacatc cttctgctca acatgctcat tgctctcatg ggtgagaccg    420
tcaacaagat tgcacaagag agcaagaaca tctggaagct gcagagagcc atcaccatcc    480
tggatacaga gaagagcttc ctgaagtgca tgaggaaggc cttccgctct ggcaagctgc    540
tgcaggtggg gttcactcct gacggcaagg atgactaccg gtggtgtttc agggtggacg    600
aggtaaactg gactacctgg aacaccaatg tgggtatcat caacgaggac ccaggcaact    660
gtgagggcgt caagcgcacc ctgagcttct ccctgaggtc aggccgagtt tcagggagaa    720
actggaagaa ctttgccctg gttccccttc tgagggatgc aagcactcga gatagacatg    780
ccacccagca ggaagaagtt caactgaagc attatacgg                           819
<210> SEQ ID NO 12
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Rattus sp.
<400> SEQUENCE: 12
ctggaaagga tggaacaacg                                                 20
<210> SEQ ID NO 13
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Rattus sp.
<400> SEQUENCE: 13
gctctagata ggaatgtgcc taggcagg                                        28

Claims

1. An isolated nucleic acid molecule encoding the amino acid sequence of SEQ ID NO:5.

2. A nucleic acid vector for recombinant expression of a human capsaicin receptor comprising a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:4, operatively linked to a nucleic acid sequence comprising at least one heterologous regulatory element in the appropriate orientation for expression.

3. The vector of claim 2, wherein the vector is a plasmid vector.

4. The vector of claim 2, herein the vector is a viral vector.

5. A recombinant cell comprising the vector of claim 2.

6. The recombinant cell of claim 5, wherein the recombinant cell is a bacterial cell.

7. The recombinant cell of claim 5, wherein the recombinant cell exhibits capsaicin agonist binding activity that significantly greater to the p≦0.05 level, as measured using a parametric test of statistical significance, than that exhibited by the host cell.

8. The recombinant cell of claim 7, wherein the recombinant cell is an insect cell.

9. The recombinant cell of claim 7, wherein the cell is an amphibian cell.

10. The recombinant cell of claim 9, wherein the amphibian cell is an oocyte.

11. The recombinant cell of claim 7, wherein the cell is a mammalian cell.

12. The recombinant cell of claim 11, wherein the cell is a HEK 293 cell.

13. An isolated nucleic acid molecule encoding the amino acid sequence of SEQ ID NO:4.

14. A nucleic acid vector for recombinant expression of a human capsaicin receptor comprising a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:5, operatively linked to a nucleic acid sequence comprising at least one heterologous regulatory element in the appropriate orientation for expression.

15. A recombinant cell comprising the vector of claim 14.